var title_f37_17_38160="Tetrahydrozoline: Patient drug information";
var content_f37_17_38160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetrahydrozoline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/55/3956?source=see_link\">",
"       Tetrahydrozoline (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/62/6116?source=see_link\">",
"       Tetrahydrozoline (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12133 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38160=[""].join("\n");
var outline_f37_17_38160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/55/3956?source=related_link\">",
"      Tetrahydrozoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/62/6116?source=related_link\">",
"      Tetrahydrozoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_17_38161="Endo MFP";
var content_f37_17_38161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasonography of the uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Triple line appearance of the endometrium in the mid-follicular phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Judith Adams, DMU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38161=[""].join("\n");
var outline_f37_17_38161=null;
var title_f37_17_38162="Congo red amyloid";
var content_f37_17_38162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congo red stain in amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Congo red stain viewed under polarized light of a renal biopsy from a patient with renal amyloidosis. Green birefringence (white arrows) of interstitial amyloid deposits can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38162=[""].join("\n");
var outline_f37_17_38162=null;
var title_f37_17_38163="Mycosis fungoides plaques";
var content_f37_17_38163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides - plaque stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, scaly plaques are visible on this patient with plaque stage mycosis fungoides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38163=[""].join("\n");
var outline_f37_17_38163=null;
var title_f37_17_38164="Azelastine (ophthalmic): Patient drug information";
var content_f37_17_38164=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azelastine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/47/17139?source=see_link\">",
"     see \"Azelastine (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/19/31026?source=see_link\">",
"     see \"Azelastine (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7977087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optivar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azelastine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The eye solution is not for care of contact lens irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store upright at room temperature. Do not freeze. Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10890 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38164=[""].join("\n");
var outline_f37_17_38164=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977087\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030896\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030895\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030900\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030901\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030903\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030898\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030899\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030904\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030905\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/53/8022?source=related_link\">",
"      Azelastine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/54/12132?source=related_link\">",
"      Azelastine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/20/5445?source=related_link\">",
"      Azelastine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/47/17139?source=related_link\">",
"      Azelastine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/19/31026?source=related_link\">",
"      Azelastine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_17_38165="Oxycodone and ibuprofen: Patient drug information";
var content_f37_17_38165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxycodone and ibuprofen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/52/26440?source=see_link\">",
"     see \"Oxycodone and ibuprofen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxycodone, ibuprofen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, bowel block, or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 30 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11228 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38165=[""].join("\n");
var outline_f37_17_38165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029978\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029980\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029979\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029984\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029985\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029987\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029982\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029983\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029988\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029989\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/52/26440?source=related_link\">",
"      Oxycodone and ibuprofen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_17_38166="Gifted writing sample 4";
var content_f37_17_38166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child at age 5 years, 10 months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When we learned about space we learned about Neptune. A fact is that Neptune has a storm cloud scooter and it chases all the other storms. I also enjoyed being with Nicholas and Nadia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38166=[""].join("\n");
var outline_f37_17_38166=null;
var title_f37_17_38167="Patient monitoring during HIV antiretroviral therapy";
var content_f37_17_38167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient monitoring during HIV antiretroviral therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/17/38167/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/17/38167/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/17/38167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/17/38167/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/17/38167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/17/38167/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/17/38167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper utilization of antiretroviral therapy (ART) requires ongoing patient monitoring to assess therapeutic response and to identify adverse events related to chronic administration of potentially toxic medications.",
"   </p>",
"   <p>",
"    This topic will address laboratory monitoring in the HIV-infected patient during ART.",
"   </p>",
"   <p>",
"    Discussions related to the initiation and modification of ART are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adherence to medications implies that the patient is taking all medication doses at the time intervals prescribed. Patients should be interviewed regarding medication adherence in a nonjudgmental manner. It is important to have a discussion about adherence at each clinic visit, since one study demonstrated that physicians incorrectly predicted adherence in 41 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/1\">",
"     1",
"    </a>",
"    ]. Patient understanding of the link between adherence and drug resistance should also be assessed.",
"   </p>",
"   <p>",
"    It is sometimes useful to discuss medication schedules with patients to help them link pill-taking behaviors to other daily activities, such as brushing teeth. If the patient admits to difficulties with adherence, potential barriers could involve the number and timing of doses, sizes of pills, food restrictions, and treatment-limiting side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another important issue for clinicians to remember is that patterns of adherence can vary over time. This was well illustrated in a study of 640 men and 1304 women; depression in men and use of alcohol in women (including binge drinking) predicted lower rates of adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinical trials have tried to assess whether directly observed therapy (DOT) may improve virologic suppression rates. One meta-analysis of 12 studies suggested that DOT seemed to offer no benefit over self-administered treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/3\">",
"     3",
"    </a>",
"    ]. However, it is still unclear as to whether DOT may be beneficial in specific patient subgroups at the greatest risk for nonadherence, such as homeless persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/4\">",
"     4",
"    </a>",
"    ]. Other interventions, such as assessing serum drug concentrations, monitoring pill counts, or use of electronic drug monitoring devices, are not routinely recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain contemporary antiretroviral medications are less affected by changes in adherence, either due to greater potency, a high genetic barrier to resistance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a long serum half-life. These advantages have allowed less stringent adherence with a lower risk of clinical consequences compared with some early antiretroviral medications. Thus, the impact of less than optimal adherence is dependent on the individual components of the ART regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2313558\">",
"    <span class=\"h2\">",
"     Medication persistence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication persistence is defined as the duration of time from initiation to discontinuation of therapy. Whereas adherence measures &ldquo;how often&rdquo; patients take their medications, persistence measures &ldquo;for how long&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/6\">",
"     6",
"    </a>",
"    ]. This concept of medication persistence is important since interruption of ART has significant consequences, not only in increased risk for opportunistic infections, but also for serious non-AIDS events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VISIT FREQUENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are started on ART should generally have follow-up within one to two weeks to ask patients about adverse effects, adherence, and prevention of transmission. Once patients are clinically stable on their ART regimen visit frequency can decrease to every three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL LABORATORY MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should obtain several tests on entry to care, before initiation of ART, and during ART. For more detailed information, see table 3 of the DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents, which can be accessed at",
"    <a class=\"external\" href=\"file://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1\">",
"     file://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The following laboratory tests are recommended at baseline and at three to six months of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      BUN and creatinine",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More frequent laboratories may be indicated if mild or moderate abnormalities are detected and the medications are continued. Hematologic monitoring is particularly important in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , which can cause bone marrow suppression, while monitoring of creatinine and urinalysis every six months is necessary in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which can cause renal sufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    should have a periodic urinalysis due to the risk of nephrolithiasis.",
"   </p>",
"   <p>",
"    More frequent monitoring may be indicated depending on the drug prescribed. For example, in patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , some experts recommend monitoring at baseline, two weeks, four weeks, eight weeks, twelve weeks, and then every three months. More importantly, patients need to be instructed about the symptoms of clinical hepatitis, particularly if they have risk factors for hepatotoxicity, such as underlying chronic viral hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In light of the metabolic disorders that can be seen in this patient population, lipid and glucose levels should be monitored at baseline, three months, six months, and then yearly (if normal). Measurements of height and weight for calculation of body mass index are advised at clinic visits; some clinics also incorporate measurements of waist circumference to detect early changes suggestive of HIV associated lipodystrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, women of childbearing age should have pregnancy testing before initiation of potentially teratogenic drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VIROLOGIC RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma HIV RNA should be measured in all patients at baseline and regularly during therapy since it is the most reliable indicator of response to ART and is useful in predicting clinical progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Many host and viral factors, including adherence and drug resistance, can affect the virologic response to ART.",
"   </p>",
"   <p>",
"    The key goal of therapy is viral load suppression below the limits of assay detection. Viral load reduction may be more rapid in patients with higher CD4 cell counts, in those with lower levels of baseline viremia, and in those who are treatment-naive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/12\">",
"     12",
"    </a>",
"    ]. The expected responses with sequential viral load determinations are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef77987 \" href=\"mobipreview.htm?7/4/7243\">",
"     table 1",
"    </a>",
"    ). To a large extent, the ability to achieve specific viral load thresholds is dependent on the baseline viral load. However, the general expectation is that the initial antiretroviral regimen will achieve the goal of a one-log decline by four weeks and a viral load &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    by 16 to 24 weeks, regardless of prior treatment experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/9,13\">",
"     9,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute illness and vaccinations can cause a transient increase in the viral load. Because of biologic variability, sequential HIV viral load measurements must exceed a threefold change or 0.5 log10",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    to be considered significantly different. Unanticipated results should be verified with a repeat test before making changes in antiretroviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Virologic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virologic failure is defined either as primary failure to achieve a viral load &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or any sustained recurrence of viremia to &gt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    after initial viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two main causes of failure to achieve virologic suppression: drug resistance or failure of the drugs to reach the target site. The latter is almost always due to problems adhering to the drug regimen, but rare causes are drug interactions or altered pharmacology due to host factors (eg, malabsorption). Drug resistance may be transmitted or acquired due to suboptimal treatment or inadequate adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Resistance mutations in patients with transmitted resistance may not be apparent with baseline testing if they are present in the minority pool. Clinicians should thoroughly evaluate any patient who demonstrates a suboptimal early response to ART:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be asked to describe how they are taking their ART regimen to detect errors in prescribing, dispensing, or patient comprehension.",
"     </li>",
"     <li>",
"      Patients should be asked how many doses they are missing in a non-judgmental manner. Patients will frequently overstate adherence and the following wording may be helpful in permitting patients to discuss adherence problems: \"HAART regimens are difficult and most patients I care for have trouble taking every dose as prescribed. How much of the prescribed medication are you actually taking?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug resistance testing should be performed in patients who attest to excellent adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Viral blips",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral \"blips\" refer to an isolated low-level of detectable HIV RNA (&gt;50 to 500",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    that occurs during long-term monitoring on a stable ART regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/21\">",
"     21",
"    </a>",
"    ]. According to the Department of Health and Human Services (DHHS) HIV treatment guidelines, viral blips do not require intervention with a new regimen unless the viral load is sustained at &gt;200",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/9\">",
"     9",
"    </a>",
"    ]. Most reports of viral blips under 200",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    represent laboratory error:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One longitudinal study with intensive HIV RNA monitoring in ten patients with a history of viral suppression for more than six months showed viral blips in 24 of 714 (3.1 percent) measurements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/22\">",
"       22",
"      </a>",
"      ]. None of these blips exceeded 200",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      and all were short lived (&lt;3 days). Finally, these viral blips were not verified in any of the simultaneous samples that were processed in another laboratory.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, viral blips should prompt discussions with patients regarding adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Adherence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The authors concluded that viral blips usually represent laboratory error.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMMUNE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral suppression is usually accompanied by an increase in CD4 count of &ge;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    at four to eight weeks followed by slower incremental increases of 50 to 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/25\">",
"     25",
"    </a>",
"    ]. The rate of increase in CD4 cells may be slower in older patients or in those with severe immunocompromise at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CD4 cell counts may increase even in patients who do not attain viral suppression. These \"discordant results\" are seen in approximately 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/27\">",
"     27",
"    </a>",
"    ]. Various hypotheses for this observed immunologic benefit in the face of ongoing viremia have been proposed including decreased replication capacity, decreased immune activation, and preservation of non-syncytium-inducing strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/28\">",
"     28",
"    </a>",
"    ]. However, this immunologic benefit is usually lost after approximately three years of continuous viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other patients may obtain viral suppression without any improvement in absolute CD4 cell counts. Risk factors for this outcome include advanced age and low nadir CD4 count. This observation has also been noted in patients treated with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which is now contraindicated.",
"   </p>",
"   <p>",
"    Compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based ART, increases in CD4 cell counts have been demonstrated to be higher with combination ART that includes",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    . The reason for these differences is unknown; the effect appears modest and not clinically significant, although it is statistically significant.",
"   </p>",
"   <p>",
"    In patients who achieve and maintain viral suppression, immunologic improvement is progressive over many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/30\">",
"     30",
"    </a>",
"    ]. In one study, all patients starting ART with more than 350 CD4+ T",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    at baseline achieved normalization of their CD4 counts over the period of observation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24186?source=see_link&amp;anchor=H25#H25\">",
"     \"Factors affecting HIV progression\", section on 'Impact of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CD4 count can be affected by interlaboratory variability, acute illness, medications that suppress the bone marrow, and diurnal variation. For these reasons, results that are unexpectedly different from prior ones should be confirmed with a repeat test. A significant difference between two test results is generally defined as a 30 percent change in the absolute CD4 count and a three digit change in CD4 percentage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FREQUENCY OF LABORATORY MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precise data are not available regarding the optimal frequency of virologic monitoring after the initiation of ART. The time to achieve an undetectable viral load depends on the potency of the regimen, drug resistance, and the baseline viral load. Once viral suppression is confirmed, HIV RNA can be measured every three to four months to confirm ongoing viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of viral load monitoring varies modestly between the two major US guideline committees.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DHHS Panel recommends HIV viral load testing at one to four weeks after initiating ART with the expectation of a decrease of at least one log (10-fold) compared to baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/9\">",
"       9",
"      </a>",
"      ]. Repeat viral load measurements should be performed at four- to eight-week intervals until the level falls below the assay's limit of detection (below 40 to 75",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      by most commercial assays).",
"     </li>",
"     <li>",
"      The IAS-USA expert panel recommends measurement of plasma HIV RNA levels at weeks two, four, eight, and every four weeks thereafter until a non-detectable viral load is confirmed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CD4 count is usually obtained in tandem with HIV RNA testing, but after it stabilizes above 350",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    some authorities recommend less frequent measurements of the CD4 count (ie, three- to six-month intervals after 2 to 3 years of stable disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After initiating ART, we recommend HIV RNA testing through standard assays every four weeks until viral suppression (&lt;50",
"    <span class=\"nowrap\">",
"     copies/microL)",
"    </span>",
"    is confirmed; Once viral suppression is attained, HIV RNA can be checked every three to four months for the first year. Patients who remain clinically stable with ongoing viral suppression and a CD4 cell count well above the threshold for risk of opportunistic infections can be monitored less frequently; in such patients, the DHHS panel recommends CD4 cell count and viral load monitoring testing every 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/9\">",
"     9",
"    </a>",
"    ]. In a EuroSIDA study of 2240 patients who maintained full viral suppression for one year on ART, the risk of subsequent virologic failure over the next year was 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/31\">",
"     31",
"    </a>",
"    ]. These data suggest that patients who have ongoing viral suppression should be given the option of having HIV RNA and CD4 cell count monitoring every six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/13\">",
"     13",
"    </a>",
"    ]. If a patient has undetectable virus but undergoes a change in regimen (eg, because of toxicity), HIV RNA should be monitored within two to eight weeks to be certain viral suppression has been maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistance testing should be performed on virus from patients who have not achieved HIV RNA suppression by 24 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with virologic failure despite appropriate adherence, HIV resistance testing should be obtained since archived mutations that were not found on baseline resistance testing may emerge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These tests usually require a viral load &gt;1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and expertise in interpretation. Testing should be performed while the patient is taking the failing regimen; ongoing drug pressure optimizes the chance of determining resistance mutations to individual components of the regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     THERAPEUTIC DRUG MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a myriad of factors that can affect serum drug levels, including liver disease, plasma protein binding and other factors. Marked interpatient variation in drugs like protease inhibitors and non-nucleoside reverse transcriptase inhibitors, has led to interest in measuring serum drug concentrations to guide dosing. However, these assays are not standardized and there are conflicting data on clinical utility. These assays are not recommended at this time for routine use in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38167/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H54#H54\">",
"     \"HIV protease inhibitors\", section on 'Therapeutic drug monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who initiate ART in the setting of a low CD4 count (typically below 50",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    may develop an immune reconstitution inflammatory syndrome (IRIS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common form of IRIS is a worsening of clinical manifestations related to an opportunistic infection (OI) in the setting of immune reconstitution.",
"     </li>",
"     <li>",
"      The second form of IRIS is de novo presentation of an OI that was presumably subclinical at the time ART was initiated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and management of immune reconstitution inflammatory syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CHANGING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common indications for changing the antiretroviral regimen include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Virologic failure",
"     </li>",
"     <li>",
"      Toxicity",
"     </li>",
"     <li>",
"      Intolerance",
"     </li>",
"     <li>",
"      Inconvenience (eg, frequency of dosing or requirements for coadministration with food)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Virologic failure should be confirmed with a second test before any treatment modification is considered. Modification of ART regimens is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/13/10451?source=see_link\">",
"       \"Patient information: Tests to monitor HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper utilization of antiretroviral therapy (ART) requires ongoing patient monitoring to assess therapeutic response and to identify adverse events related to chronic administration of potentially toxic medications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be interviewed regarding medication adherence at each clinic visit in a nonjudgmental manner. Patient understanding of the link between adherence and drug resistance should also be assessed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are started on ART should generally have follow-up within one to two weeks to ask patients about adverse effects, adherence, and prevention of transmission. Once patients are clinically stable on their ART regimen, visit frequency can decrease to every three months. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Visit frequency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine laboratory monitoring includes a complete blood count with differential, BUN and creatinine and liver function tests on a quarterly basis. Liver function testing should be performed at 2, 4, 8, and 12 weeks during the first three months of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      administration; patients should be instructed to call their providers if they have symptoms of hepatotoxicity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General laboratory monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initiating ART, HIV RNA should be measured at two to eight weeks until the viral load is undetectable on standard assays (&lt;50",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      At that point, the viral load can be measured every three to six months to confirm ongoing viral suppression. CD4 cell counts should be monitored every three to six months initially and then every 6 to 12 months once viral suppression has been confirmed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Virologic response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Immune response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virologic failure is defined either as primary failure to achieve a viral load &lt;50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      or any sustained recurrence of viremia to &gt;50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      after initial viral suppression. Lack of viral suppression may be due to drug resistance or lack of adherence. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Virologic failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral blips, defined as transient viremia with detection of HIV RNA between 50 and 200",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      usually represent laboratory error and should not be confused with virologic failure, unless low levels of viremia are sustained.",
"     </li>",
"     <li>",
"      In patients with virologic failure despite appropriate adherence, HIV resistance testing should be obtained. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Drug resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic drug monitoring is not routinely recommended at this time. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Therapeutic drug monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who initiate ART in the setting of advanced AIDS may develop an immune reconstitution inflammatory syndrome with worsening of clinical symptoms and signs related to an underlying opportunistic infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Immune reconstitution inflammatory syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/1\">",
"      Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/2\">",
"      Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007; 45:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/3\">",
"      Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 2009; 374:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/4\">",
"      Myers JE, Tsiouris SJ. Is there a place for directly observed therapy in HAART? Lancet 2009; 374:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/5\">",
"      Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/6\">",
"      Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011; 25:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/7\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/8\">",
"      Szczech LA. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context. J Infect Dis 2008; 197:7.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on August 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/10\">",
"      Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/11\">",
"      Thi&eacute;baut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epid&eacute;miologie du SIDA en Aquitaine (GECSA). AIDS 2000; 14:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/12\">",
"      Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/13\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/14\">",
"      Ghani AC, Ferguson NM, Fraser C, et al. Viral replication under combination antiretroviral therapy: a comparison of four different regimens. J Acquir Immune Defic Syndr 2002; 30:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/15\">",
"      Maggiolo F, Migliorino M, Pirali A, et al. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000; 25:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/16\">",
"      Demeter LM, Hughes MD, Coombs RW, et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001; 135:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/17\">",
"      Rousseau MN, Vergne L, Montes B, et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/18\">",
"      Alexander CS, Dong W, Chan K, et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 2001; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/19\">",
"      Eron JJ, Haubrich R, Lang W, et al. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. J Acquir Immune Defic Syndr 2001; 26:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/20\">",
"      Torre D, Tambini R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 2002; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/21\">",
"      Sungkanuparph S, Overton ET, Seyfried W, et al. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/22\">",
"      Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/23\">",
"      Podsadecki TJ, Vrijens BC, Tousset EP, et al. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 2007; 196:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/24\">",
"      Gallant JE. Making sense of blips. J Infect Dis 2007; 196:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/25\">",
"      Le Moing V, Thi&eacute;baut R, Ch&ecirc;ne G, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/26\">",
"      Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/27\">",
"      Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/28\">",
"      Sufka SA, Ferrari G, Gryszowka VE, et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis 2003; 187:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/29\">",
"      Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/30\">",
"      Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/31\">",
"      Reekie J, Mocroft A, Sambatakou H, et al. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS 2008; 22:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38167/abstract/32\">",
"      Hirsch MS, G&uuml;nthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3770 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38167=[""].join("\n");
var outline_f37_17_38167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2313558\">",
"      Medication persistence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VISIT FREQUENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL LABORATORY MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VIROLOGIC RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Virologic failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Viral blips",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMMUNE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FREQUENCY OF LABORATORY MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DRUG RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      THERAPEUTIC DRUG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INDICATIONS FOR CHANGING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/4/7243\" title=\"table 1\">",
"      Virologic response to treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=related_link\">",
"      HIV and the older patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/13/10451?source=related_link\">",
"      Patient information: Tests to monitor HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_17_38168="Central centrifugal cicatricial alopecia";
var content_f37_17_38168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Central centrifugal cicatricial alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Central centrifugal cicatricial alopecia is a form of scarring alopecia. An area of hair loss is present on the vertex of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38168=[""].join("\n");
var outline_f37_17_38168=null;
var title_f37_17_38169="M mode scan I";
var content_f37_17_38169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50635%7ECARD%2F62680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50635%7ECARD%2F62680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiographic scan of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transducer is positioned at the left parastenal region and is moved from the apex to the base of the heart. The scan shows the left ventricle (LV), the right ventricle (RV) and right ventricular outflow tract (RVOT), the mitral valve leaflets, the aorta (Ao), aortic valve (AV) and the left atrium (LA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    M mode echocardiogram scan of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transducer is positioned at the left parasternal area and is moved from the base to the apex. The scan that is obtained shows the aorta (Ao), aortic valve, the mitral valve, interventricular septum, the left ventricular (LV) chamber and the apex of the LV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38169=[""].join("\n");
var outline_f37_17_38169=null;
var title_f37_17_38170="Treatment of radiation injury in the adult";
var content_f37_17_38170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of radiation injury in the adult",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/17/38170/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/17/38170/contributors\">",
"     John R Wingard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/17/38170/contributors\">",
"     Nicholas Dainiak, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/17/38170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/17/38170/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/17/38170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/17/38170/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/17/38170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of industrial and medical radiation accidents and the threat of terrorist events involving radioactive material mandate the development and implementation of an appropriate medical response. Medical professionals who would logically be involved in such events include, among others, radiation safety officers, radiologists, radiation oncologists, nuclear medicine physicians, emergency department physicians, hematologists, medical oncologists, gastroenterologists, infectious disease specialists, as well as primary care providers. All will be asked to play a significant role in evaluating and treating victims of an accidental or deliberate exposure to radiation. Due to their experience in managing patients with cytopenias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marrow aplasia, hematologists will most likely be asked to take primary or consultative responsibility for medically treating individuals exposed to a moderate or high dose of radiation.",
"   </p>",
"   <p>",
"    However, all physicians, and especially medical triage personnel, must have an understanding of how radiation alters the function of cells, tissues, and organ systems, how radiation levels are quantified, and how victims receiving a significant radiation dose can be recognized and categorized. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scenarios have been developed for response to terrorist events resulting in small volume as well as mass casualties. The Strategic National Stockpile Radiation Working Group has developed a consensus opinion to provide guidance for estimating radiation dose, clinical assessment of exposed individuals, and medical management of those patients suffering from acute radiation injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/1\">",
"     1",
"    </a>",
"    ]. Responding medical personnel must also be aware of local, state, and national resources that may be employed in the case of a radiation accident from whatever cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/2\">",
"     2",
"    </a>",
"    ]. These subjects, as well as the treatment of patients with radiation injuries, will be discussed here.",
"   </p>",
"   <p>",
"    Treatment of radiation accidents in children is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25193?source=see_link\">",
"     \"Management of radiation exposure in children following a nuclear disaster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCENARIOS FOR RADIATION ACCIDENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive radiation doses may result from a number of different exposures, as described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Accidental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidental exposure involves the release of radioactivity from small, usually sealed, sources (ie, nuclear medicine, brachytherapy, industrial gauges, small calibration sources), accidental overtreatment with radiation therapy, transportation accidents, and nuclear power plant accidents.",
"   </p>",
"   <p>",
"    With the exception of accidents at nuclear reactor sites, such as Chernobyl, such exposures have usually involved only a small number of persons and a small area of nuclear contamination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H14#H14\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Sources of data on radiation effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Deliberate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of deliberate exposure to radiation might include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An attack on a nuclear power plant",
"     </li>",
"     <li>",
"      A malevolent act using simple radiologic devices, such as sealed sources of radiation",
"     </li>",
"     <li>",
"      Terrorist use of a radiological dispersal device (RDD or \"dirty bomb\") using a small or large source of radioactivity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spent nuclear fuel",
"     </li>",
"     <li>",
"      Detonation of an improvised nuclear device (IND) or a nuclear weapon using a critical mass of fissionable material (eg, weapons-grade uranium or plutonium)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two most likely scenarios would involve either an RDD or IND, with the former being more probable. Both warrant further discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Radiologic dispersion devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the United States Federal Government's accounting office, approximately 10 million \"sealed sources\" of radioactive material exist in 50 countries, including the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/4\">",
"     4",
"    </a>",
"    ]. These sources of radioactive material (eg, Cesium-137, Strontium-90, Cobalt-60, Plutonium-238, Plutonium-239) are encased in metal and are used in equipment for medical, industrial, agricultural, and research purposes. Of the 612 sealed sources that were reported lost or stolen since 1995, 254 have not been recovered. Many additional sealed sources may be unaccounted for as well.",
"   </p>",
"   <p>",
"    Such material may be used by terrorists for making an RDD. When used with conventional explosives, radioactive substances may be dispersed over a relatively limited area (eg, a few city blocks) with the intent to cause fear or panic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. RDDs prepared with a radioactive powder, solution, or gas may be dispersed over a larger area, and pose a minimal radiation threat, but will result in a large number of persons presenting for concerns of radiation exposure.",
"   </p>",
"   <p>",
"    An important exception to this is the scenario in which the patient is imbedded with radioactive fragments or shrapnel. These will be highly radioactive and can result in significant radionecrosis of local tissue in a short period of time, requiring urgent removal. Procedures for removing such fragments are described below (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Removal of radioactive fragments'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Improvised nuclear devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;An improvised nuclear device (IND) employs radioactive material which, following detonation, results in a nuclear reaction (eg, atom bomb, hydrogen bomb). Fission, the splitting of the atom, is exploited in a nuclear detonation. An uncontrolled fission chain reaction generates an enormous amount of energy in a small period of time. This process results in the generation of three forms of energy, which are released from such nuclear explosions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heat (approximately 35 percent of total energy)",
"     </li>",
"     <li>",
"      Shock or bomb blast (approximately 50 percent)",
"     </li>",
"     <li>",
"      Radiation (approximately 15 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The blast wave from a nuclear explosion results in fractures, lacerations, rupture of viscera, pulmonary edema, hemorrhage, and embolic events, while the thermal energy causes flash burns, flame burns, flash blindness, and retinal burns. Regardless of the source of radioactive material, the presence of multiple injuries is a mortality multiplier, owing to the predisposition to infection from trauma and burns, compounded by the immunosuppression and cytopenias caused by radiation doses as low as 0.5 Gy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H19#H19\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Hematopoietic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, it has been estimated that 65 to 70 percent of the injuries sustained in a nuclear war will be varying combinations of burns, wounds, and irradiation, while the remainder will be single injuries equally divided between irradiation and burns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Generation of radionuclides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generation of radionuclides consequent to a nuclear weapon detonation occurs as a result of byproduct generation during nuclear fission as well as through neutron activation of stable elements, which are usually ground sources (eg, soil). The primary fission products, radionuclides, constitute a spectrum of hundreds of species with differing half-lives and varying biologic importance.",
"   </p>",
"   <p>",
"    Many of these nuclides are the starting point of their own decay chain. These radionuclides continue to decay, releasing radiation, until they finally become stable. The principal nuclides per megaton of fission are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef77241 \" href=\"mobipreview.htm?37/12/38091\">",
"     table 1",
"    </a>",
"    ). Knowledge of these radionuclides becomes important and clinically meaningful as may be encountered during or subsequent to fallout (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Thyroid protection'",
"    </a>",
"    below). The clinician may encounter them in an externally or internally contaminated patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL TRIAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of an accident or intentional event involving nuclear material, the first responders will likely include members of a HAZMAT team, local fire and police departments, and individuals knowledgeable in radiological monitoring from a state agency, such as the State Department of Environmental Protection. Many states have or will be setting up Weapons of Mass Destruction- Civil Support Teams, which can significantly augment the command system and can deploy within four hours at the request of a governor or the President of the United States.",
"   </p>",
"   <p>",
"    With the advent of the Department of Homeland Security (DHS), numerous monetary grants have been awarded to enhance the capabilities of first responders. Moreover, DHS's significant restructuring of numerous federal agencies has unified numerous efforts. One of the seminal efforts has been the development of the National Response Plan (NRP). The NRP is a single all-discipline, all-hazards plan. This comprehensive plan revolutionizes the federal response to terrorism, major disasters, and other emergencies by treating crisis management and consequent management as a single integrated function under DHS.",
"   </p>",
"   <p>",
"    The NRP also includes the implementation of the National Incident Management System (NIMS) to ensure that all levels of government are able to work together during a disaster. In the event of a significant detonation, the Initial NRP calls for self deployment of several federal assets and agencies, including the Federal Bureau of Investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Their responsibilities are to manage the consequences of the incident by means of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/1,3,5\">",
"     1,3,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protecting the public",
"     </li>",
"     <li>",
"      Limiting further damage",
"     </li>",
"     <li>",
"      Monitoring the extent and types of radioactivity present",
"     </li>",
"     <li>",
"      Performing decontamination",
"     </li>",
"     <li>",
"      Disposing of radioactive material",
"     </li>",
"     <li>",
"      Making decisions concerning evacuation, relocation, shelter, need for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      , as well as guidance for other protective actions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medical centers, in turn, must develop and rehearse radiation response plans that coordinate their efforts with those of local, state, regional, and national response teams.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prehospital triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial triage will be performed by first-responders, who will not enter a radiation environment until the extent of the hazard is known. A HAZMAT team will likely self-deploy and arrive on the scene early on to guide other responders. Some first responders may carry electronic pocket dosimeters that would alert them to the presence of radiation. All participants should be volunteers whenever possible.",
"   </p>",
"   <p>",
"    First responders should work in teams and should be monitored with physical dosimetry if possible. In a true emergency, the equivalent dose to a large portion of an emergency responder's body may approach 0.5 Sv (50 rem) in a short time. The volunteer needs to understand the associated risk for potential acute effects, which are minimal to none, but that there may be some increased risk for subsequent malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H6#H6\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Examples of possible radiation exposures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    First responders will receive protective action guidance. Early on, data may be sparse, and this will be based on the best scientific guess. Protective gear should include eye protection, respiratory protection, gloves, and physical dosimetry if possible. Clothes and a fire fighter's bunker gear will afford some protection of the skin. First responders and all other health care providers must use strict isolation precautions (disposable gowns, double gloves, masks, cap, shoe covers) for personal protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Outer gloves should be changed often to avoid cross-contamination. Protective gear should be removed after use and placed in a clearly labeled, sealed plastic container.",
"   </p>",
"   <p>",
"    Early management in the field and the emergency department should follow basic triage principles (",
"    <a class=\"graphic graphic_table graphicRef76009 \" href=\"mobipreview.htm?15/49/16156\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Life-threatening injuries, if present, should be treated even before assessing the amount of radiation exposure. It should be assumed that all victims are contaminated, either by absorption of radiation through the skin after being physically covered by radioactive material or by ingestion or by inhalation of radioactive material. Victims should be stabilized and transported to a medical facility.",
"     </li>",
"     <li>",
"      Injured victims should be treated by standard triage guidelines. Preliminary decontamination (ie, removal of clothing, washing of the victim) should remove 90 to 95 percent of external contamination.",
"     </li>",
"     <li>",
"      If there are many victims, persons who are externally contaminated and are without other injury should be relocated to an upwind site other than the hospital in order to decongest the hospital care system. Thereafter, assessment and prevention of contamination, treatment of minor injuries, and evaluation and treatment of internal contamination should be addressed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Removal of radioactive fragments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers involved in the removal of radioactive fragments or shrapnel from an exploded device must first consult the radiation safety officer (RSO). Shielding barriers, which are found in many operating rooms owing to their need in brachytherapy insertion and removal, will afford some protection.",
"   </p>",
"   <p>",
"    Finger ring dosimeters should be worn by physicians removing such fragments. At a minimum they should be worn on the dominant hand, although having one on each hand is optimal. Unfortunately, these dosimeters are not read locally. However, an electronic pocket dosimeter (EPD) could be taped on the forearm, under the gown, for real-time reading. The RSO can then calculate the dose to the fingers based on this reading and the operating distance.",
"   </p>",
"   <p>",
"    Physicians should work in teams with frequent monitoring of radiation doses so that exposure time can be minimized; pregnant personnel should be excluded from such efforts. Removed fragments should be placed into a lead container and covered. Both finger ring dosimeters and suitable lead containers are available from the medical center's Nuclear Medicine department. These steps should significantly minimize the risk to the provider and lessen their risk of local radiation injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     In hospital triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers should be well-trained and rehearsed and must also use strict isolation precautions (eg, disposable gowns, double gloves, masks, cap, eye protection, and shoe covers) for personal protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Inner gloves should be taped to the gown and outer gloves should be changed often to avoid cross-contamination. If possible, contaminated patients should enter the treatment facility through a separate entrance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25193?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of radiation exposure in children following a nuclear disaster\", section on 'Treatment area'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, physical dosimeters should be worn under the gown and monitored to ensure provider safety, but this should not preclude caring for the patient. Protective gear should be removed after use and placed in a clearly labeled, sealed plastic container. Hospital personnel should also be monitored for contamination prior to leaving the area or after decontaminating themselves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Safety of health care providers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of health care providers is of paramount importance. Health care providers should approach the patient as though he or she has been contaminated with human blood, body fluids, or raw sewage. This requires donning a gown, mask, double gloves, cap, and shoe covers. Outer gloves should be changed frequently to avoid cross-contamination. Following use, protective gear should be removed and placed in a labeled, sealed plastic container.",
"   </p>",
"   <p>",
"    Provided that these universal precautions are taken, it is extremely unlikely that radioactive contamination will occur, even when treating a patient with a heavy burden of radioactive material. In fact, there are no reports of health care workers who have adhered to this protocol becoming contaminated from handling such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/1\">",
"     1",
"    </a>",
"    ]. All hospital personnel should be assessed for contamination when leaving the treatment area and decontaminated, if required.",
"   </p>",
"   <p>",
"    Additional precautions need to be taken when the patient is imbedded with radioactive fragments. These are discussed above (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Removal of radioactive fragments'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After arrival in the emergency department, victims should be classified based on whether or not they have been contaminated with radioactive material, received a significant external radiation exposure without contamination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    received physical injury.",
"   </p>",
"   <p>",
"    The vast majority of individuals arriving in the emergency department after an event involving an RDD are likely to have insignificant or no exposure. Clinicians should be able to identify those victims whose exposure is significant, using principles presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H8#H8\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Assessment of radiation dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When necessary, and if not already performed, victims should be decontaminated after clinical assessment of injury severity has been made. Depending on the situation, a trauma surgeon, burn specialist, dermatologist, gastroenterologist,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurologist may be consulted, in addition to the hematologist. Information regarding risk level should be provided to medical caregivers by the medical center's radiation safety officer, radiologist, nuclear medicine physician,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation oncologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History taking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical information, including the location of the incident, duration of exposure, interval between exposure and clinical evaluation, activity and exact location at the time of exposure, and occupation of the victim should be documented in the medical record. Other information, such as a general description of the accident, source of radiation, and numbers of individuals involved in the exposure should be documented, whenever possible.",
"   </p>",
"   <p>",
"    Generally, the clinical signs and symptoms of radiation exposure are nonspecific. However, the presence or absence of nausea, vomiting, diarrhea, abdominal cramping",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding, fatigue, fever, and mental changes should be noted. If the patient has experienced vomiting, the time of onset after the exposure should be noted as accurately as possible, since such information is of extreme importance in estimating the degree of radiation exposure (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H12#H12\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Biological dosimetry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include vital signs (fever, hypotension, orthostatic changes), skin examination (erythema, blistering, edema, desquamation), neurologic examination (level of consciousness, ataxia,",
"    <span class=\"nowrap\">",
"     motor/sensory",
"    </span>",
"    deficits, presence or absence of reflexes, papilledema), gastrointestinal examination (abdominal tenderness, gastrointestinal bleeding) and hematologic examination (ecchymoses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    petechiae of mucous membranes and skin).",
"   </p>",
"   <p>",
"    A schema has been developed to assess the severity of changes in the clinical examination according to standardized cutaneous (",
"    <a class=\"graphic graphic_table graphicRef62805 \" href=\"mobipreview.htm?5/28/5580\">",
"     table 4",
"    </a>",
"    ), gastrointestinal (",
"    <a class=\"graphic graphic_table graphicRef70498 \" href=\"mobipreview.htm?29/14/29931\">",
"     table 5",
"    </a>",
"    ), cerebrovascular (",
"    <a class=\"graphic graphic_table graphicRef53121 \" href=\"mobipreview.htm?32/44/33484\">",
"     table 6",
"    </a>",
"    ), and hematopoietic (",
"    <a class=\"graphic graphic_table graphicRef51611 \" href=\"mobipreview.htm?16/21/16732\">",
"     table 7",
"    </a>",
"    ) radiation injury scoring systems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H15#H15\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Phases of acute radiation injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Initial laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If internal contamination is suspected, collection and monitoring of secretions and excreta can be helpful. For example, obtaining bilateral nasal swab samples within the first hour of the incident can provide valuable information. As an example, the extent of nares contamination is approximately 5 percent of that received by the pulmonary alveoli. For victims in whom internal contamination is suspected, peripheral blood (for the same tests as ordered for an external exposure), urine, nasal smears, spontaneous vomitus, and stools should be obtained for radiological monitoring. Hospital staff must take precautions with the handling of these samples as they may be radioactive. Any patient with wound contamination or imbedded with radioactive fragments should be evaluated for such internal contamination.",
"   </p>",
"   <p>",
"    Initial laboratory testing should include a complete blood count (CBC) with white blood cell differential and platelet count, along with routine chemistry tests. The time of CBC collection must be carefully noted, because of important time-related changes in the lymphocyte count (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If possible, serial CBCs should then be obtained every 6 to 12 hours for at least three samples. Twenty-four hours after any significant exposure, a blood sample should be drawn into a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    tube and sent to an appropriate referral lab for confirmatory chromosomal aberration analysis. This information may also aid in the patient's management and the determination of overall prognosis (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional monitoring should be based on the whole-body dose, as the onset of neutropenia and its severity are dose dependent (",
"    <a class=\"graphic graphic_figure graphicRef65095 \" href=\"mobipreview.htm?16/2/16431\">",
"     figure 1",
"    </a>",
"    ). Patients with low exposures may need a weekly or twice-weekly CBC for 4 to 6 weeks to document their WBC nadir and subsequent recovery.",
"   </p>",
"   <p>",
"    For patients felt to have internal contamination, a 24-hour urine and stool sample every day for four days should be collected and analyzed for radionuclide contamination. Treatment guidance should be based on expert assistance, such as that obtained from the NCRP Report 65, Management of Persons Accidentally Contaminated with Radionuclides. Advice is also available on the following website:",
"    <a class=\"external\" href=\"file://www.orau.gov/reacts\">",
"     www.orau.gov/reacts",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     High risk populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose to the gravid uterus is approximately 65 to 70 percent of that received on the surface, affording some protection to the fetus from external radiation. However, when internal radiation contamination is present, the fetus may receive a high dose due to its proximity to the maternal bladder. In addition, the fetal thyroid begins to take up iodine after 12 weeks, adding to the potential for injury (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Thyroid protection'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25193?source=see_link\">",
"     \"Management of radiation exposure in children following a nuclear disaster\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because the fetus is very susceptible to the effects of ionizing radiation, any pregnant female exposed to radiation should also see a health physicist and a maternal fetal medicine specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several unique features encountered in children enhance their vulnerability to the effects of radiation. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17689?source=see_link\">",
"     \"Clinical features of radiation exposure in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25193?source=see_link\">",
"     \"Management of radiation exposure in children following a nuclear disaster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased susceptibility to radiation is also encountered in elderly patients. This results from an inherently diminished bone marrow reserve as well as the increased likelihood of co-morbidities, increasing the risk for development of anemia, bleeding,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT DECISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management decisions must be made for high-risk individuals when results of individual biodosimetry (eg, chromosomal analysis, lymphocyte kinetics) are not yet available. One approach to the decision-making process, developed by the Medical Treatment Protocols (METREPOL) team, is to assign a score based upon clinical and routine laboratory findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/9\">",
"     9",
"    </a>",
"    ]. This application is very detailed and may be useful in a radiation accident in which a small number of casualties are present, but is impractical in a mass casualty scenario.",
"   </p>",
"   <p>",
"    Integration of clinical information regarding the severity of signs and symptoms (",
"    <a class=\"graphic graphic_table graphicRef62805 \" href=\"mobipreview.htm?5/28/5580\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70498 \" href=\"mobipreview.htm?29/14/29931\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53121 \" href=\"mobipreview.htm?32/44/33484\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51611 \" href=\"mobipreview.htm?16/21/16732\">",
"     table 7",
"    </a>",
"    ), along with the presence and timing of the onset of vomiting, and changes in peripheral blood counts (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"     table 3",
"    </a>",
"    ) permits one to assess the severity of exposure to ionizing radiation in quantitative terms.",
"   </p>",
"   <p>",
"    A \"response category\" is assigned to each victim, determined by the highest degree of severity in any of the signs or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/9\">",
"     9",
"    </a>",
"    ]. Using this information and results of hematologic monitoring, victims can be triaged to the ambulatory setting, routine care",
"    <span class=\"nowrap\">",
"     medical/surgical",
"    </span>",
"    floor, intensive care unit or transplantation unit, as outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef80123 \" href=\"mobipreview.htm?19/0/19470\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Assessing prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose estimates provide an added level of certainty with regard to prognosis, and impact on selection of therapy (",
"    <a class=\"graphic graphic_table graphicRef53570 \" href=\"mobipreview.htm?28/5/28764\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57598 \" href=\"mobipreview.htm?9/18/9516\">",
"     table 9",
"    </a>",
"    ). In order to facilitate the integration of clinical, laboratory, and dosimetric data, a radiation casualty management software program (ie, the Biological Assessment Tool) has been developed by the Armed Forces Radiobiology Research Institute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/11\">",
"     11",
"    </a>",
"    ]. Background information and advice on clinical management of radiation incidents can be obtained at this website and at the website for",
"    <span class=\"nowrap\">",
"     REAC/TS",
"    </span>",
"    (",
"    <a class=\"external\" href=\"file://www.orau.gov/reacts\">",
"     www.orau.gov/reacts",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is important to recognize those patients who may need no or minimal care, as well as those whose degree of radiation exposure precludes survival (",
"    <a class=\"graphic graphic_table graphicRef76009 \" href=\"mobipreview.htm?15/49/16156\">",
"     table 2",
"    </a>",
"    ). These two groups are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Minimally exposed patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with exposures of less than 0.5 to 1.0 Gy will invariably survive, provided there are no other life-threatening complications of the exposure (eg, bomb blast, burns, fractures). These patients can be recognized by the following signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No or minimal prodromal symptoms (ie, anorexia, apathy, nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea) (",
"      <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53570 \" href=\"mobipreview.htm?28/5/28764\">",
"       table 8",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H16#H16\">",
"       \"Biology and clinical features of radiation injury in adults\", section on 'Prodromal phase'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      No or minimal (degree 1) gastrointestinal system changes (",
"      <a class=\"graphic graphic_table graphicRef70498 \" href=\"mobipreview.htm?29/14/29931\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      No cerebrovascular system changes (",
"      <a class=\"graphic graphic_table graphicRef53121 \" href=\"mobipreview.htm?32/44/33484\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      No or minimal decline in lymphocyte count, absolute neutrophil count, or platelet count 24 to 48 hours after exposure (",
"      <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51611 \" href=\"mobipreview.htm?16/21/16732\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients do not require hospitalization, and may need no medical care. Nausea and vomiting, if present, are usually mild and transient, and usually abate within two to three days. Reassurance and psychological care are essential, however, especially in mass casualty settings (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Psychosocial impact'",
"    </a>",
"    below). Accordingly, ambulatory monitoring with psychosocial support may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fatal outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with exposures in excess of 10 to 12 Gy have virtually no chance of survival. Depending on therapy, death is certain within days to weeks following exposure, despite any and all treatments. Such patients will present with the following signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset of vomiting within 30 minutes to one hour following exposure (",
"      <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe or marked cerebrovascular system changes (degree 3 or 4) (",
"      <a class=\"graphic graphic_table graphicRef53121 \" href=\"mobipreview.htm?32/44/33484\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe degrees of lymphopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decline of &ge;50 percent in absolute lymphocyte count within 24 hours of exposure (",
"      <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a mass casualty scenario, a more simplified strategy employing military triage principles should be considered (",
"    <a class=\"graphic graphic_table graphicRef76009 \" href=\"mobipreview.htm?15/49/16156\">",
"     table 2",
"    </a>",
"    ). This triage model focuses life saving efforts and resource expenditures on those with more survivable injuries and triages those with highly mortal wounds to the expectant category. Such patients should be provided with comfort measures, such as management of pain, vomiting, and diarrhea. Psychological support and pastoral care are essential for helping the patient and family through such devastating exposures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Psychosocial impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychosocial impact of an act of terrorism cannot be overemphasized. Many victims will have psychological symptoms, ranging from insomnia and hypervigilance to social withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/12\">",
"     12",
"    </a>",
"    ]. Posttraumatic stress disorder may occur among victims, families, and friends. High-risk victims include children, pregnant women, mothers of young children, and victims with a prior medical history of psychiatric disorders. The principle of therapy is to establish trust through open communication. Approaches to management of behavioral and mental health problems in similar settings (eg, atom bomb survivors, nuclear reactor accidents) have been presented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/13-17\">",
"     13-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     INITIAL MEDICAL AND SURGICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention, when required, should be carried out within 36 hours, and not later than 48 hours after exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/18\">",
"     18",
"    </a>",
"    ]. Additional surgery, if required, should not be performed until at least six weeks post-exposure, in order to assure recovery from the period of cytopenia and immunosuppression, which would otherwise seriously add to the risk of developing surgical complications (ie, infection, poor wound healing). Precautions for removal of radioactive fragments are described above (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Removal of radioactive fragments'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the importance of the time elapsed between radiation exposure and the onset of vomiting in determining individual radiation dose, prophylaxis against vomiting is not initially desired, and may also be impractical given the short time to onset of vomiting with clinically significant exposures (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"mobipreview.htm?7/34/7725\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, at low exposure doses, vomiting usually abates after 48 to 72 hours; therefore, prolonged antiemetic therapy is not usually warranted.",
"   </p>",
"   <p>",
"    If treatment is required, the use of serotonin receptor antagonists is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/20\">",
"     20",
"    </a>",
"    ]. Neuroleptic antiemetics may also be employed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=see_link\">",
"     \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     General supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues requiring active or preventative treatment include any or all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintaining normal vital signs and assuring an open airway. These are especially important in those sustaining additional injuries (eg, blast damage, burns, trauma)",
"     </li>",
"     <li>",
"      Rapid replacement of fluid, electrolyte, and blood losses, especially in those presenting with shock, hypotension, significant burns, hypovolemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multiorgan failure shortly after exposure",
"     </li>",
"     <li>",
"      Seizure control, if present",
"     </li>",
"     <li>",
"      Control of nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea",
"     </li>",
"     <li>",
"      Judicious use of analgesics, anxiolytics, sedatives",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hematologic support (eg, transfusion of blood components, use of cytokines, hematopoietic cell transplantation) should be considered in those having estimated exposures in the range of 2 to 10 Gy. This subject is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Management of the hematopoietic radiation injury syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-neutropenic patients, use of antibiotics should be reserved for obvious foci of infection secondary to extensive burns, penetrating wounds,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     abdominal/visceral",
"    </span>",
"    trauma. Since altering the anaerobic gut flora has worsened outcomes in irradiated animals, antibacterial gut prophylaxis should only be administered in patients with an abdominal wound or C. difficile enterocolitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/21\">",
"     21",
"    </a>",
"    ] or in patients with critical illness in the intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Thyroid protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of significant exposure to radioactive isotopes of iodine (eg, nuclear reactor incident, atomic blast), prevention of significant uptake of radioactive isotopes of Iodine, especially Iodine-131, by the thyroid is imperative. This is especially important in the exposed fetus after the 12th week of gestation, as well as in the child or adolescent, all of whom are most prone to the development of radiation-induced thyroid carcinoma. This form of the thyroid cancer also appears to be biologically more aggressive than de novo forms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1818?source=see_link&amp;anchor=H16#H16\">",
"     \"Radiation-induced thyroid cancer\", section on 'Potassium iodide for thyroid protection in a nuclear accident'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     Potassium iodide",
"    </a>",
"    (KI) is available in 130 mg tablets. A one-time oral dose of 130 mg is recommended for pregnant or lactating women and adults &gt;18 years of age (",
"    <a class=\"graphic graphic_table graphicRef69996 \" href=\"mobipreview.htm?35/13/36059\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/23\">",
"     23",
"    </a>",
"    ]. Oral KI should be administered as soon as possible, preferably less than 6 hours after the exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/24\">",
"     24",
"    </a>",
"    ]. However, if it anticipated that a person will be exposed to radioactive iodine for more than 24 hours, additional doses should be taken every 24 hours. Guidance and KI recommendations will be provided by emergency management officials after an incident. Information on the use of potassium iodide as a thyroid blocking agent in radiation emergencies can be found on the FDA website at: &lt;",
"    <a class=\"external\" href=\"file://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080542.pdf\">",
"     www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080542.pdf",
"    </a>",
"    &gt; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE HEMATOPOIETIC RADIATION INJURY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful administration of supportive care in the",
"   </p>",
"   <p>",
"    non-hematopoietic stem cell transplant scenario is dependent upon all of the following conditions being present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nonhematopoietic injuries (eg, cerebrovascular, gastrointestinal, and cutaneous syndromes, as well as radiation-induced lung injury and other trauma) are survivable. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"       \"Radiation-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation-induced damage to hematopoietic stem and progenitor cells is reversible.",
"     </li>",
"     <li>",
"      Hematopoietic regeneration results in the production of adequate numbers of functionally normal neutrophils and platelets within the critical, clinically manageable period (ie, approximately two to six weeks following radiation exposure), or the patient will not survive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate management of the hematologic complications of radiation injury requires judicious and prompt use of blood products, antibiotics, hematopoietic cytokines, as well as the possible use of hematopoietic cell transplantation in a select number of victims who have no other injuries or significant toxicity to other organs.",
"   </p>",
"   <p>",
"    Physicians with experience in the clinical management of patients with prolonged cytopenias, complications of total body irradiation, and their infectious sequelae are best prepared for management of patients with the hematopoietic radiation injury syndrome. This will likely involve hematologists, medical and radiation oncologists, and physicians skilled in hematopoietic cell transplantation. These patients may have additional complexity, owing to injuries to the cutaneous and mucosal barriers, as well as other radiation- or trauma-related organ toxicities. Specialists from all disciplines will be required in their management. These issues are discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/1,26\">",
"     1,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early experimental work demonstrated the efficacy of supportive care following radiation exposures. Specifically, controlling infection and bleeding during the critical neutropenic and thrombocytopenic phases was the limiting factor in successful treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. For example, in one study the",
"    <span class=\"nowrap\">",
"     LD50/30",
"    </span>",
"    value (ie, the radiation dose lethal to 50 percent of the study subjects in 30 days) in canines increased significantly from 2.6 Gy without supportive care to approximately 3.4 Gy following use of supportive care alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/30\">",
"     30",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     LD50/30",
"    </span>",
"    was prolonged further to 5.5 Gy following the early addition of hematopoietic colony stimulating factors. Similar results have also been reported for non-human primates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/31-37\">",
"     31-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean lethal dose of radiation required to kill 50 percent of humans at 60 days",
"    <span class=\"nowrap\">",
"     (LD50/60)",
"    </span>",
"    is a whole-body radiation dose between 3.25 to 4 Gy in persons managed without any supportive care, and 6 to 7 Gy when antibiotics and transfusion support are provided. Extrapolating from the survival benefit demonstrated in animal studies, the lethal dose may be somewhat higher with early initiation of colony stimulating factors. However, a whole-body dose &gt;10 Gy is likely to be lethal.",
"   </p>",
"   <p>",
"    Given the similarities between patients with the hematopoietic radiation injury syndrome and those undergoing hematopoietic cell transplantation, many of the fundamentals in supportive care, prophylaxis, blood product support, and infection management remain the same. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     BLOOD PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood product support is required for patients with severe degrees of cytopenia resulting from radiation-induced bone marrow aplasia and for those with anemia secondary to gastrointestinal and other blood losses. Severe degrees of anemia and thrombocytopenia do not typically occur before one to two weeks following exposure, during which time additional blood donors may be identified for blood product support for large numbers of injured patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Irradiation of blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cellular blood products should be irradiated (25 Gy) to prevent transfusion-associated graft-versus- host disease (TA-GVHD), a life threatening form of acute GVHD that occurs in immunosuppressed patients given blood products containing viable proliferating allogeneic lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TA-GVHD is almost uniformly fatal and may be difficult to distinguish from other organ toxicities seen in radiation victims (eg, fever, pancytopenia, skin rash, diarrhea, and abnormal liver function). Fortunately, this complication is fully preventable through the irradiation of cellular blood products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Leukoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukoreduction is known to lessen febrile nonhemolytic reactions and the immunosuppressive effects of blood transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. It also affords some protection against platelet alloimmunization and cytomegalovirus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/40\">",
"     40",
"    </a>",
"    ]. However, leukoreduction alone is not sufficient to protect patients from transfusion-induced GVHD. Irradiation of all blood products is the only way to assure complete safety from the latter complication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accordingly, all blood products should be irradiated and, if possible, leukoreduced whenever time and facilities permit. However, when this is not possible, life-saving blood products should not be withheld.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Transfusion guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for transfusion of red cells and platelets should follow those recommended for patients recovering from chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef52206 \" href=\"mobipreview.htm?11/29/11741\">",
"     table 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H558395349#H558395349\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Leukemia and chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support with granulocyte transfusions may sometimes be useful for controlling refractory infections during the period of neutropenia, but as yet has not been formally evaluated in controlled trials of subjects with radiation injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4393?source=see_link&amp;anchor=H4#H4\">",
"     \"Granulocyte transfusions\", section on 'Minimal criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient or permanent cytopenias after radiation exposure develop as a result of damage to bone marrow stem cells and progenitor cells. Depending on radiation dose, cytopenias may improve transiently, causing an \"abortive rise\" in the circulating neutrophil count (",
"    <a class=\"graphic graphic_figure graphicRef65095 \" href=\"mobipreview.htm?16/2/16431\">",
"     figure 1",
"    </a>",
"    ) or may inexorably progress. Hematopoietic recovery following radiotoxicity occurs through proliferation of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Undamaged",
"      <span class=\"nowrap\">",
"       stem/progenitor",
"      </span>",
"      cells that escape from exposure due to inhomogeneously irradiated bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Relatively radioresistant",
"      <span class=\"nowrap\">",
"       stem/progenitor",
"      </span>",
"      cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whereas infusion of hematopoietic",
"    <span class=\"nowrap\">",
"     stem/progenitor",
"    </span>",
"    cells is required to successfully treat irreversible cytopenias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/42\">",
"     42",
"    </a>",
"    ], cytokines may accelerate hematopoietic recovery in the case of reversible hematopoietic toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Neutrophil recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/43\">",
"     43",
"    </a>",
"    ] and in a small number of radiation accident victims [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/44,45\">",
"     44,45",
"    </a>",
"    ] have demonstrated an apparent beneficial effect of cytokines on neutrophil recovery in man. Controlled trials of cytokine therapy in mice, non-human primates, and canines have also shown improved survival after lethal irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/32,46,47\">",
"     32,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the available cytokines has formal FDA approval for the management of radiation-induced aplasia of the bone marrow. Nevertheless, based upon results of studies in irradiated animals and an apparent shortening of the period of granulocytopenia in victims of radiation accidents, cytokines are recommended under some circumstances after radiation exposure. An analysis by an expert panel convened by the World Health Organization of cytokine effects in five reported radiation accidents resulted in a strong recommendation for the administration of cytokines when the absolute neutrophil count (ANC) is",
"    <span class=\"nowrap\">",
"     &lt;500/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/48\">",
"     48",
"    </a>",
"    ]. This assessment utilized the Grading of Recommendations Assessment Development and Evaluation (GRADE) system to determine cytokine effects on ANC and overall survival among individuals with documented bone marrow failure after accidental exposure to ionizing radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/48\">",
"     48",
"    </a>",
"    ]. Cytokines were found to be most beneficial to granulopoiesis in patients with an absorbed dose of &lt;5Gy.",
"   </p>",
"   <p>",
"    Guidelines for use of cytokines in acute radiation injury have been developed in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/1\">",
"     1",
"    </a>",
"    ] and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/49\">",
"     49",
"    </a>",
"    ]. Expert opinion suggests that cytokines should be administered soon after (ie, within 24 hours) an exposure of &gt;3Gy has occurred or when clinical signs and symptoms indicate a level 3 degree of hematotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H19#H19\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Hematopoietic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lower threshold exposure dose (ie, 2 Gy) should be considered for initiation of cytokine therapy in children &lt;12, adults &gt;60, and individuals of any age who have mechanical injuries",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thermal burns. All individuals with an absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &lt;500/microL",
"    </span>",
"    should be considered for cytokine therapy.",
"   </p>",
"   <p>",
"    Granulocyte-colony stimulating factor (G-CSF) at a dose of 5",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    of body weight per day subcutaneously has been recommended as treatment in this setting. Other cytokines (eg, pegylated G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF)) may be considered. Cytokine therapy should be continued for 2 to 3 weeks or until the absolute neutrophil count is",
"    <span class=\"nowrap\">",
"     &gt;1000/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Stimulation of erythropoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    or darbepoetin in this setting has not been established, but can be considered in patients with persistent anemia and a hematocrit &lt;30 percent. A baseline serum erythropoietin level may be helpful, and supplementation with iron should be considered if these agents are employed. Clinical benefit may not be seen for three to six weeks. A weak recommendation for the use of these erythropoiesis-stimulating agents was made by the WHO panel of experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link&amp;anchor=H17#H17\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Treatment issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     ANTIBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility to local and systemic infection after radiation arises as a result of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breeches in cutaneous and mucosal barriers",
"     </li>",
"     <li>",
"      Immune suppression and neutropenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in irradiated mice have demonstrated that normal endogenous gut flora undergo a dose-related reduction in numbers within the first four days postradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/21,50\">",
"     21,50",
"    </a>",
"    ]. This is followed by a relative increase in the number of Enterobacteriaceae compared with anaerobic bacteria by the 12th day. Fatal bacteremia may then result from the bacterial translocation of these organisms. Quinolone use was effective in controlling systemic endogenous Gram-negative infections after radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Supplementation with penicillin prevented treatment failures due to Streptococci and increased survival in animals. Quinolones given for 21 days were also effective in preventing endogenous Klebsiella and Pseudomonas infections in preclinical models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/21,51,52\">",
"     21,51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infections during neutropenia caused by myelosuppressive chemotherapy or radiation treatment regimens are bacterial. The risk for life-threatening infection is particularly high when the absolute neutrophil count (ANC) is &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    As in animals, antibiotic prophylaxis provides a protective benefit that in meta-analyses has been associated with fewer infections, fewer bacteremic episodes, lower infection-related mortality, and improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While controversy exists over prophylaxis with the fluoroquinolones, their use has been explored extensively for prophylaxis in high-risk neutropenic patients and has demonstrated a reduction in the incidence of infectious episodes and bacteremic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/54-58\">",
"     54-58",
"    </a>",
"    ], and in meta-analyses improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/53,59\">",
"     53,59",
"    </a>",
"    ]. Consideration for their use should be given to patients with profound neutropenia (ie, ANC &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    expected to persist for &gt;10 days.",
"   </p>",
"   <p>",
"    Fever during neutropenia is most commonly due to a bacterial infection. In patients who experience neutropenic fever, the recommendations of consensus panels, such as the Infectious Diseases Society of America and National Comprehensive Cancer Network for evaluation and management are sensible guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. For patients receiving fluoroquinolone prophylaxis, the fluoroquinolone should be stopped and the patient should undergo a prompt fever workup, including physical examination and blood cultures. Parenteral therapy, directed at gram-negative bacteria, and in particular, Pseudomonas aeruginosa, should be instituted urgently, as gram negative infections may be rapidly lethal.",
"   </p>",
"   <p>",
"    This serves as the minimum backbone of antibiotic usage. Additional antimicrobials should be added to broaden coverage as clinically required to treat other foci of infection secondary to mucosal or integument injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The IDSA clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer, as well as other IDSA guidelines, can be accessed through the Infectious Diseases Society of America's web site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin and respiratory bacteria may be important pathogens, more so than in the cancer patient, if there is significant injury to the integument or damage to respiratory mucosal epithelium by burns or inhalation of radioactive particulates. Antibiotics with coverage against Gram positive bacteria may need to be considered in such situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Fungal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive Candida infections are the most frequent fungal pathogens in neutropenic patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    has been shown to lessen mucosal and invasive Candida fungal infections and fungal-related mortality in patients undergoing allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/63,64\">",
"     63,64",
"    </a>",
"    ] at doses of 200 to 400 mg by mouth daily. Data in patients receiving conventional forms of severely myelotoxic chemotherapy also have demonstrated benefits in using this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/65\">",
"     65",
"    </a>",
"    ], although conflicting results exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Fluconazole prophylaxis is ineffective against aspergillus, molds, Candida krusei, and resistant Candida species. Invasive infections by mould pathogens become increasingly more problematic when neutropenia persists for more than two weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The opportunistic pathogen Pneumocystis jirovecii (formerly pneumocystis carinii) is classified as a fungus. It has unique tropism for the lungs, with rare dissemination. Patients with profound T-helper cell depletion (ie, absolute CD4 count",
"    <span class=\"nowrap\">",
"     &lt;200/microL)",
"    </span>",
"    are at risk for infection. Prophylaxis is warranted, given its associated high mortality, although no defined guidelines for monitoring of the CD4 count in irradiation patients exist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link&amp;anchor=H29#H29\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\", section on 'Pneumocystis carinii (jirovecii) prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, extrapolating from the HIV and stem cell transplant experience, for patients who have survived a significant radiation exposure, the absolute CD4 count should be assessed at approximately day 30 post-exposure, and then every 3 to 6 months until the absolute CD4 count is",
"    <span class=\"nowrap\">",
"     &gt;200/microL.",
"    </span>",
"    Initiation and maintenance of prophylaxis is recommended if the absolute CD4 count is",
"    <span class=\"nowrap\">",
"     &lt;200/microL.",
"    </span>",
"    In patients with persistent myelosuppression,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    should be avoided as it may worsen existing cytopenias. Atovoquine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    are alternative agents. Discontinuation of prophylaxis can be considered when the absolute CD4 count is",
"    <span class=\"nowrap\">",
"     &gt;200/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of intense immunosuppression, patients with radiation injury are at risk for herpes simplex virus (HSV) reactivation, which may be confused with radiation stomatitis and may complicate its management by adding to the severity of mucosal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H10#H10\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Mucositis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Herpes simplex virus (HSV) serological status should be determined if resources allow, and prophylaxis should be employed, using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    in those who are serologically positive for HSV types I or II. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .) Because of intense immunosuppression, these patients are at high risk for HSV reactivation, which may be confused with radiation stomatitis and may complicate its management by adding to the severity of mucosal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H10#H10\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Mucositis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If HSV serologies are not known, HSV prophylaxis can be reasonably offered based on any previous history of oral or genital herpes infections. Additionally, any patient not receiving prophylaxis and suffering from mucositis, especially if unusually severe or prolonged, should be assessed for possible HSV reactivation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of reactivation of cytomegalovirus (CMV) in those patients harboring a latent CMV infection may be increased; the degree to which this causes CMV disease and its attendant mortality is unknown. If resources permit, CMV serologic status should be assessed. If the patient is CMV seronegative, blood products from CMV seronegative donors should be provided whenever possible. Alternatively, leukoreduced products provide a protective effect against transmission of CMV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link&amp;anchor=H11#H11\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Viral diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of this uncertainty, CMV antigen or PCR assessment should be performed weekly from approximately days 30 to 100 post-exposure. Frequently, detection of CMV in blood antedates disease by one to two weeks.",
"   </p>",
"   <p>",
"    Patients with evidence of early CMV viremia should be treated preemptively, prior to the development of CMV disease, with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    . For those patients with a history of CMV reactivation and continued T-cell immunodeficiency (ie, CD4 count",
"    <span class=\"nowrap\">",
"     &lt;50/microL),",
"    </span>",
"    more protracted monitoring should be considered, such as every other week until 6 months post-exposure. Appropriate consultation with an Infectious Disease consultant followed by appropriate therapy should be instituted for those patients who develop CMV disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is anticipated that these patients will be at high risk for infection due to an enhanced susceptibility to many pathogens, including atypical fungi and other viruses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .) Some viral infections may be newly acquired and others may be due to reactivation. A high index of suspicion is required, especially in patients with culture negative fever and those with fever and pulmonary infiltrates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those who experience significant neutropenia (ie, absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &lt;500/microL),",
"    </span>",
"    broad spectrum prophylactic antimicrobials should be employed, as the neutropenic duration is likely to be prolonged (",
"    <a class=\"graphic graphic_table graphicRef57598 \" href=\"mobipreview.htm?9/18/9516\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65095 \" href=\"mobipreview.htm?16/2/16431\">",
"     figure 1",
"    </a>",
"    ). Prophylaxis should include a fluoroquinolone (FQ) with streptococcal coverage (or penicillin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    added to the FQ if it is not inherently covered by the FQ), an antiviral agent if the patient is herpes simplex virus (HSV) positive, and an antifungal agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These agents should be continued until the patient fails treatment, develops toxicity, experiences a neutropenic fever, or experiences neutrophil recovery (ANC",
"    <span class=\"nowrap\">",
"     &gt;500/microL).",
"    </span>",
"    Any foci of infection that develop during the neutropenic period will require a full course of antibiotic therapy.",
"   </p>",
"   <p>",
"    In patients who experience neutropenic fever, therapy should follow the recommendations of the Infectious Diseases Society of America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/61\">",
"     61",
"    </a>",
"    ]. For patients receiving fluoroquinolone prophylaxis, the fluoroquinolone should be stopped and the patient should undergo a fever work-up. Parenteral therapy, directed at gram-negative bacteria, and in particular, Pseudomonas aeruginosa, is administered urgently, as gram negative infections may be rapidly lethal.",
"   </p>",
"   <p>",
"    This serves as the minimum backbone of antibiotic usage. Additional microbials should be added to broaden coverage as clinically required to treat other foci of infection secondary to mucosal or integument injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Historical perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scientific basis for treatment with hematopoietic cell transplantation (HCT) was developed by demonstrating that experimental animals could be protected against lethal hematopoietic injury by intravenous infusion of bone marrow cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/69\">",
"     69",
"    </a>",
"    ]. Given this background, it would seem obvious that HCT might be utilized to treat patients with severe bone marrow injury from a radiation overdose. However, the use of HCT in these patients is complicated by a variety of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation exposure is often not homogeneous. For example, patients might have bone marrow ablative doses of radiation to parts of their body, but other marrow-containing structures might be minimally or unirradiated. This can come about because the patient was partially shielded by an automobile, desk, wall, or other barrier.",
"     </li>",
"     <li>",
"      Concomitant injuries such as burns or trauma can greatly complicate the care of patients who also have radiation-induced bone marrow failure. In a compilation of 58 patients who had potentially lethal radiation exposure, the major causes of deaths were burns (55 percent), hemorrhage (41 percent), infection (15 percent), and acute respiratory distress syndrome (15 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/70\">",
"       70",
"      </a>",
"      ]. Obviously, HCT would not have repaired the vast majority of these fatal injuries.",
"     </li>",
"     <li>",
"      Explosion of a nuclear device leading to mass casualties would also destroy the infrastructure necessary to care for these patients. Losses would include not only hospital centers and supplies, but also medical, nursing, and ancillary personnel. The likelihood of identifying patients who might benefit from HCT seems slim when hospital beds and the necessary personnel to carry out sophisticated support services have also been damaged or destroyed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using HCT to treat radiation victims requires an accurate assessment of exposure. As an example, doses below 3 Gy would usually not be fatal if excellent nursing care was available, and the upper dose limit that can be survived without HCT might be in the range of 7 Gy following the prompt use of hematopoietic growth factors and aggressive supportive care. On the other hand, doses in excess of 10 Gy are likely to be fatal because of injury to organ systems other than bone marrow (eg, cerebrovascular and gastrointestinal). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link&amp;anchor=H8#H8\">",
"     \"Biology and clinical features of radiation injury in adults\", section on 'Assessment of radiation dose'",
"    </a>",
"    .) This leaves only a small fraction of patients who might benefit from HCT (ie, doses of 7 to 10 Gy for those receiving allogeneic HCT and 4 to 10 Gy for those able to receive autologous or syngeneic HCT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H881196\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of radiation incident registries indicated that of 31 patients who underwent HCT, 27 patients died, and the remaining four patients survived with a rejected allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/42\">",
"     42",
"    </a>",
"    ]. Using the GRADE system, the WHO panel of experts analyzed outcomes from HCT in three reported radiation accidents, and determined that the majority of transplant recipients developed non-hematopoietic organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/48\">",
"     48",
"    </a>",
"    ]. Survival was more likely among individuals receiving &lt;9 Gy and no HCT. A weak recommendation was made for the administration of HCT to irradiated individuals after failure of two to three weeks of cytokine treatment to induce recovery from marrow failure in the absence of non-hematopoietic organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Case selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most favorable situation would involve a patient who had fully compatible hematopoietic stem cells immediately available for an autologous hematopoietic cell transplantation. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Military personnel at high risk might have such cells stored for emergency purposes",
"     </li>",
"     <li>",
"      Patients may have stored stem cells as a potential backup treatment for a previously documented malignancy",
"     </li>",
"     <li>",
"      Patients may have their own umbilical cord blood in long-term storage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=see_link\">",
"       \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with identical twins (syngeneic HCT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It would seem wise to be liberal in the use of HCT to treat these patients and to err on the side of overutilization, since complications of either autologous or syngeneic HCT in this setting should be minimal.",
"   </p>",
"   <p>",
"    However, it is unlikely that victims of radiation overexposure fall into any of the above settings or even know that they have an HLA matched sibling. It is even more unlikely that a patient would have had a recently completed search for a matched unrelated donor. The ability to carry out either of these activities after a radiation event depends upon the size of the event and the number of injured victims. However, it is possible that HLA typing of siblings or an accelerated search for an unrelated donor might be accomplished when the number of victims is small.",
"   </p>",
"   <p>",
"    A haplotype-matched donor might be considered, especially in children. Unfortunately, available data on the treatment of radiation injury with allogeneic HCT are not encouraging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 29 patients who underwent HCT after accidental radiation overdose, the median survival was only 33 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/70\">",
"       70",
"      </a>",
"      ]. While all 29 patients had some evidence of engraftment (ie, 10 to 100 percent of bone marrow cells being of donor origin) 14 days post-transplant, there was no evidence for permanent engraftment in any of the survivors.",
"     </li>",
"     <li>",
"      All patients with burns died and only three patients survived for more than one year, two following infusion of bone marrow stem cells and one following use of fetal liver cells. It is impossible to determine whether or not their survival was related to the HCT, since no survivor had permanent donor engraftment.",
"     </li>",
"     <li>",
"      In 7 of the 29 patients (24 percent) graft-versus-host disease (GVHD) was felt to be a major contributing cause of death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were observed in two radiation accidents in Japan, where two of three victims received allogeneic HCT plus cytokine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/71\">",
"     71",
"    </a>",
"    ]. One patient received a mismatched unrelated umbilical cord blood HCT and the other received a HLA identical sibling donor HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/72\">",
"     72",
"    </a>",
"    ]. Both transplanted patients demonstrated transient donor cell engraftment followed by autologous hematopoietic recovery before eventually dying of other radiation injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to be optimistic about a major contribution of HCT in the treatment of patients with radiation injury. The chance of identifying patients with lethal marrow injury, no lethal injury to other organs, no severe burns or trauma, and an intact medical infrastructure, seems poor. The prognosis for a transplant patient following radiation injury would be even worse",
"    <span class=\"nowrap\">",
"     if/when",
"    </span>",
"    additional complications occur, such as infection and respiratory failure. In particular, a mass casualty situation requires an early estimation of prognosis in order to appropriately address available resources to those most likely to survive admission to an intensive care unit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44598?source=see_link\">",
"     \"Intensive care for oncology patients: Short-term prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=see_link\">",
"     \"Ethics in the intensive care unit: Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the rare patient with a significant exposure (ie, 4 to 10 Gy) who might have an autologous or syngeneic HCT option, a stem cell infusion should be considered, as it would have low morbidity and would likely lead to earlier hematologic reconstitution, which might be lifesaving (",
"    <a class=\"graphic graphic_table graphicRef57598 \" href=\"mobipreview.htm?9/18/9516\">",
"     table 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If resources allow, the use of a matched sibling or unrelated allogeneic HCT can be considered in the rare patient with a significant exposure (ie, 7 to 10 Gy), with minimal to no extramedullary injuries, and with a rapidly identified volunteer donor. Additional considerations should be given to the exploration of novel transplant methods (eg, non-myeloablative HCT) and stem cell sources (eg, umbilical cord blood HCT) in this small subset of irradiated victims deemed eligible for such treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     OTHER MEDICAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Immune reconstitution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune reconstitution in some patients will likely be aberrant and radiation dose-dependent, especially since single fraction total body irradiation (TBI) is more immunosuppressive than fractionated TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extrapolating from the transplantation literature, functional hyposplenism may occur following transplantation with total body irradiation-containing regimens. However, many of these patients had allogeneic HCT and also had chronic graft-versus-host disease. It is difficult to predict the extent to which radiation may affect splenic function, but it should be assessed as a potential long-term risk for those patients with a significant exposure who survive the event.",
"   </p>",
"   <p>",
"    Accordingly, convalescent serologies should be assessed at one year following any significant whole body exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link&amp;anchor=H17005404#H17005404\">",
"     \"Laboratory evaluation of the immune system\", section on 'Antibody deficiency and defects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, one should consider monitoring of immunoglobulin levels in these patients, especially in the presence of recurrent sinopulmonary infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link&amp;anchor=H37#H37\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\", section on 'Immunoglobulins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous immunoglobulin is not ordinarily required in patients with reduced IgG levels unless recurrent sinopulmonary infections occur. In patients receiving intravenous immunoglobulin for longer than one year, delayed immune production of immunoglobulins may occur. Moreover, revaccination of patients who have received immunoglobulin replacement within three months may yield a suboptimal response.",
"   </p>",
"   <p>",
"    Revaccination should follow the",
"    <span class=\"nowrap\">",
"     CDC/ASBMT/IDSA",
"    </span>",
"    guidelines with the additional consideration of vaccination for polysaccharide encapsulated organisms such as Streptococcal pneumonia, Neisseria meningococcus, and Hemophilus influenzae type B if functional hyposplenism is suspected. Repeat serologies to assess vaccination efficacy is warranted.",
"   </p>",
"   <p>",
"    The IDSA clinical practice guidelines for preventing opportunistic infections among HSCT recipients, as well as other IDSA guidelines, can be accessed through the Infectious Diseases Society of America's web site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunization of unaffected family members can be useful to reduce the risk of exposure to infectious agents and provide some protection to the patient during the period before immunization is possible. The patient should avoid exposure to any individual who has received the oral polio vaccine, since transmission of virus is possible for weeks after the immunization. The inactivated polio vaccine is advisable for family members to avoid risk of transmission.",
"   </p>",
"   <p>",
"    If a serologic response is not achieved, use of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    or another antibiotic with activity against encapsulated bacteria should be considered. Live vaccines should not be given until at least 24 months after exposure and should only be done in patients with some evidence of immune recovery. This may require consultation with an Immunologist.",
"   </p>",
"   <p>",
"    There is a substantial clinical database showing that myelosuppressive chemotherapy or myeloablative conditioning prior to HCT has deleterious effects on immune recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7561?source=see_link&amp;anchor=H11#H11\">",
"     \"Secondary immune deficiency due to miscellaneous causes\", section on 'Ionizing radiation'",
"    </a>",
"    .) To date, there is no effective treatment for the prolonged T cell deficiencies associated with cytotoxic therapy. The significant delay in regeneration of CD4 + T cells, marked imbalance in the",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio, and a limited T-cell receptor repertoire leave the patient at risk for infectious complications.",
"   </p>",
"   <p>",
"    Several cytokines, including the Interleukins (IL)-2, 4, 7, 17, c-kit ligand (KL), flt-3 (FL), thymic stromal lymphopoietin (TSLP), and keratinocyte growth factor (KGF) have been associated with T-cell differentiation, proliferation, and enhanced thymopoiesis and functional recovery of peripheral T cells in investigational studies, but there is no experience with their use in subjects with radiation injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/78-83\">",
"     78-83",
"    </a>",
"    ]. This subject is explored in depth separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Internal contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate skin and wound decontamination will eliminate or reduce uptake of radioactivity from these routes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25193?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of radiation exposure in children following a nuclear disaster\", section on 'Contamination'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Initial triage'",
"    </a>",
"    above.) However, organ doses from internal emitters are rarely high enough to cause the acute radiation syndrome. Accordingly, treatment decisions concerning internal contamination will primarily involve concerns about late health effects, such as radiation-induced carcinogenesis.",
"   </p>",
"   <p>",
"    These treatment considerations should take into account the age and co-morbidities of the patient. For example, children are more radiosensitive than adults and have a longer life expectancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17689?source=see_link\">",
"     \"Clinical features of radiation exposure in children\"",
"    </a>",
"    .) In contrast, older patients with significant co-morbidities are less likely to benefit from treatment of internal contamination, as they may not live long enough to manifest long-term sequelae.",
"   </p>",
"   <p>",
"    If radioactive isotopes of iodine are present,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    (KI) blockade of thyroid should be initiated",
"    <strong>",
"     immediately",
"    </strong>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H31\">",
"     'Thyroid protection'",
"    </a>",
"    above). Ideally, patients would already have KI present in their homes, with a priority of treatment directed toward those with the highest risk of subsequent development of thyroid cancer.",
"   </p>",
"   <p>",
"    Any patient with evidence to suggest internal contamination (eg, by history, a positive nasal swab, or known wound contamination) should be examined to ascertain the principal radionuclides present consequent to the exposure. The metabolic behavior of the radionuclides present and their biologic significance can then be ascertained. This assessment should be undertaken with guidance from the radiation safety officer and may include examination of the radionuclide content in the excreta (urine and stool) and",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    employment of a whole-body counter.",
"   </p>",
"   <p>",
"    Goals of treatment are based on the radionuclides present and current knowledge of their clinical consequences. Treatment principles may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inhibition of absorption from the GI tract",
"     </li>",
"     <li>",
"      Blocking organ uptake (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Employment of isotope dilution",
"     </li>",
"     <li>",
"      Alteration of the chemistry of the contaminating substance",
"     </li>",
"     <li>",
"      Displacement of the isotope from its receptors",
"     </li>",
"     <li>",
"      Employment of chelation",
"     </li>",
"     <li>",
"      Lung lavage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The table presents a brief overview of selected internal contaminants and their potential treatment (",
"    <a class=\"graphic graphic_table graphicRef54615 \" href=\"mobipreview.htm?43/23/44411\">",
"     table 12",
"    </a>",
"    ). A number of excellent sources are available for clinical guidance on this subject. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NCRP 65: \"Medical Management of Radiation Accidents\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The Radiation Emergency Assistance",
"      <span class=\"nowrap\">",
"       Center/Training",
"      </span>",
"      Site",
"      <span class=\"nowrap\">",
"       (REAC/TS),",
"      </span>",
"      <a class=\"external\" href=\"file://www.orau.gov/reacts\">",
"       www.orau.gov/reacts",
"      </a>",
"      , has expertise in radiation injury, including internal contamination management. This Department of Energy asset also maintains a 24 hour emergency hotline: 1-865-576-1005 (ask for",
"      <span class=\"nowrap\">",
"       REAC/TS).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h1\">",
"     DISASTER PLANNING AND ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning in 2001, the National Marrow Donor Program and the American Society for Blood and Marrow Transplantation established the Radiation Injury Treatment Network (RITN), a voluntary consortium of 52 transplant centers, donor centers, and umbilical cord blood banks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/85\">",
"     85",
"    </a>",
"    ]. The European Group for Blood and Marrow Transplantation is establishing a similar network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/49,86\">",
"     49,86",
"    </a>",
"    ]. The purpose of these networks is to develop treatment guidelines for managing hematologic toxicity among victims of radiation exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/17/38170/abstract/87\">",
"     87",
"    </a>",
"    ], educate healthcare professionals about radiation exposure management, coordinate response after a radiation event, and provide evaluation and treatment for victims at participating transplant centers.",
"   </p>",
"   <p>",
"    Further guidance on the management of radiation exposure is available as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       United States Health and Human Services Radiation Emergency Medical Management",
"      </strong>",
"      &ndash; This website provides comprehensive guidance on diagnosis and treatment of a wide variety of radiation emergencies including nuclear reactor accidents, nuclear explosions, and radiological dispersal devices (eg, dirty bomb) at",
"      <a class=\"external\" href=\"file://www.remm.nlm.gov/\">",
"       www.remm.nlm.gov",
"      </a>",
"     </li>",
"     <li>",
"      <strong>",
"       Oak Ridge Institute for Science and Education (ORISE",
"      </strong>",
"      ) &ndash; Hospital triage and medical aspects of radiation incidents, including detailed procedure demonstrations for decontamination are available at",
"      <a class=\"external\" href=\"file://orise.orau.gov/reacts/resources/radiation-faq.aspx\">",
"       file://orise.orau.gov/reacts/resources/radiation-faq.aspx",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <strong>",
"       World Health Organization (WHO)",
"      </strong>",
"      &ndash; WHO maintains a website that provides useful information and documents for download in the event of an international radiation accident or emergency at",
"      <a class=\"external\" href=\"file://www.who.int/ionizing_radiation/a_e/en\">",
"       www.who.int/ionizing_radiation/a_e/en",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <strong>",
"       Regional poison control centers",
"      </strong>",
"      &ndash; In the United States, regional poison control centers are available to provide radiation exposure information and resources (eg, access to local radiation safety officers). To obtain emergency consultation, call 1-800-222-1222. The World Health Organization maintains a list of international poison centers at",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13328959\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13335265\">",
"    <span class=\"h2\">",
"     Initial response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of radiation accidents and the threat of terrorist events involving radioactive material mandate the development and implementation of an appropriate medical response, the components of which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial triage with removal of radioactive fragments, if present. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial triage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical and laboratory assessment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of prognosis to determine who should or should not be treated. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Assessing prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13333138\">",
"    <span class=\"h2\">",
"     Treatment measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, there is only one treatment protocol for radiation-induced injury. The fundamentals of such management should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive supportive care consisting of fluids, antibiotics, platelets, and other blood components. All cellular products require leukoreduction and irradiation. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Initial medical and surgical management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Blood products'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H42\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of one of the granulopoietic cytokines should be considered as soon as possible following exposure (",
"      <a class=\"graphic graphic_table graphicRef66044 \" href=\"mobipreview.htm?27/46/28395\">",
"       table 13",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      to those whose injuries resulted from a nuclear reactor accident or from a nuclear device detonation (",
"      <a class=\"graphic graphic_table graphicRef69996 \" href=\"mobipreview.htm?35/13/36059\">",
"       table 10",
"      </a>",
"      ). Priority should be given to children and pregnant women. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Thyroid protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation should be considered only in highly selected patients. (See",
"      <a class=\"local\" href=\"#H51\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/1\">",
"      Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004; 140:1037.",
"     </a>",
"    </li>",
"    <li>",
"     Hall EJ. Radiobiology for the Radiologist, 5th ed, Lippincott, Williams &amp; Wilkins, Philadelphia 2000.",
"    </li>",
"    <li>",
"     Management of terrorist events involving radioactive material. NCRP Report No.138, National Council on Radiation Protection and Measurements Bethesda, MD 2001. p.125.",
"    </li>",
"    <li>",
"     Second General Accounting Office Report on Sealed Radioactive Sources. June 16, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/5\">",
"      Mettler FA Jr, Voelz GL. Major radiation exposure--what to expect and how to respond. N Engl J Med 2002; 346:1554.",
"     </a>",
"    </li>",
"    <li>",
"     The federal response plan: FEMA 229. Federal Emergency Medical Agency, Washington, DC 1999.",
"    </li>",
"    <li>",
"     Weapons of mass destruction incident contingency plan. Federal Bureau of Investigation, Washington, DC 1998.",
"    </li>",
"    <li>",
"     Additional information available on the Oak Ridge Associated Universities website at www.orau.gov/reacts (Accessed on August 10, 2004).",
"    </li>",
"    <li>",
"     Fliedner TM, Friesecke I, Beyrer K. Medical Management of Radiation Accidents: Manual on the Acute Radiation Syndrome, British Inst Radiol, Oxford 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/10\">",
"      Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol 2002; 30:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/11\">",
"      Sine RC, Levine IH, Jackson WE, et al. Biodosimety Assessment Tool: a post-exposure software application for management of radiation accidents. Mil Med 2001; 166:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/12\">",
"      Becker SM. Psychosocial assistance after environmental accidents: a policy perspective. Environ Health Perspect 1997; 105 Suppl 6:1557.",
"     </a>",
"    </li>",
"    <li>",
"     Mental Health and Mass Violence, Evidence-Based Early Psychological Intervention for Victims/Survivors of Mass Violence. NIH Pub.02-5138. Washington, DC: National Institute of Mental Health Workshop; 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/14\">",
"      Bromet EJ, Gluzman S, Schwartz JE, Goldgaber D. Somatic symptoms in women 11 years after the Chornobyl accident: prevalence and risk factors. Environ Health Perspect 2002; 110 Suppl 4:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/15\">",
"      Bromet EJ, Havenaar JM, Guey LT. A 25 year retrospective review of the psychological consequences of the Chernobyl accident. Clin Oncol (R Coll Radiol) 2011; 23:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/16\">",
"      Dew MA, Bromet EJ, Schulberg HC, et al. Mental health effects of the Three Mile Island nuclear reactor restart. Am J Psychiatry 1987; 144:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/17\">",
"      Loganovsky K, Havenaar JM, Tintle NL, et al. The mental health of clean-up workers 18 years after the Chernobyl accident. Psychol Med 2008; 38:481.",
"     </a>",
"    </li>",
"    <li>",
"     Medical consequences of nuclear warfare. Walker RI, Cerveny RJ (Eds). Office of the Surgeon General 1989. Available at www.afrri.usuhs.mil (Accessed on August 10, 2004).",
"    </li>",
"    <li>",
"     Goans RE. Clinical care of the radiation-accident patient: patient presentation, assessment, and initial diagnosis. In: The medical basis for radiation-accident preparedness: The clinical care of victims, Ricks RC, Berger ME, O'Hara FM (Eds), Parthenon, Washington, DC 2002. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/20\">",
"      Abbott B, Ippoliti C, Bruton J, et al. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 1999; 23:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/21\">",
"      Brook I, Elliott TB, Ledney GD, Knudson GB. Management of postirradiation sepsis. Mil Med 2002; 167:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/22\">",
"      Dainiak N, Gent RN, Carr Z, et al. Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. Disaster Med Public Health Prep 2011; 5:183.",
"     </a>",
"    </li>",
"    <li>",
"     Additional information available at www.bt.cdc.gov/radiation/ki.asp (Accessed on August 10, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/24\">",
"      Zanzonico PB, Becker DV. Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout. Health Phys 2000; 78:660.",
"     </a>",
"    </li>",
"    <li>",
"     www.rbdd.org (Accessed on July 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/26\">",
"      Dainiak N, Waselenko JK, Armitage JO, et al. The hematologist and radiation casualties. Hematology Am Soc Hematol Educ Program 2003; :473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/27\">",
"      JACKSON DP, SORENSEN DK, CRONKITE EP, et al. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia. J Clin Invest 1959; 38:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/28\">",
"      PERMAN V, CRONKITE EP, BOND VP, SORENSEN DK. The regenerative ability of hemopoietic tissue following lethal x-irradiation in dogs. Blood 1962; 19:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/29\">",
"      Sorensen DK, Bond VP, Cronkite EP, Perman V. An effective therapeutic regimen for the hemopoietic phase of the acute radiation syndrome in dogs. Radiation Res 1960; 13:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/30\">",
"      MacVittie TJ, Monroy R, Vigneulle RM, et al. The relative biological effectiveness of mixed fission-neutron-gamma radiation on the hematopoietic syndrome in the canine: effect of therapy on survival. Radiat Res 1991; 128:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/31\">",
"      Neelis KJ, Dubbelman YD, Qingliang L, et al. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol 1997; 25:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/32\">",
"      Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996; 97:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/33\">",
"      Farese AM, Williams DE, Seiler FR, MacVittie TJ. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood 1993; 82:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/34\">",
"      Farese AM, Casey DB, Vigneulle RM, et al. A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells 2001; 19:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/35\">",
"      SCHLUMBERGER HG, VAZQUEZ JJ. Pathology of total body irradiation in the monkey. Am J Pathol 1954; 30:1013.",
"     </a>",
"    </li>",
"    <li>",
"     Stanley RE, Seigneur LJ, Strike TA. The acute mortality response of monkeys (Macacca mulatta) to mixed gamma-neutron radiations and 250 kVp X rays.SR66-23. Bethesda, MD: Armed Forces Radiobiology Research Institute 1966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/37\">",
"      Broerse JJ, Van Bekkum DW, Hollander CF, Davids JA. Mortality of monkeys after exposure to fission neutrons and the effect of autologous bone marrow transplantation. Int J Radiat Biol Relat Stud Phys Chem Med 1978; 34:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/38\">",
"      Blajchman MA. Immunomodulation and blood transfusion. Am J Ther 2002; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/39\">",
"      H&eacute;bert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/40\">",
"      Narvios AB, Lichtiger B. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Haematologica 2001; 86:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/41\">",
"      Inoue T, Hirabayashi Y, Mitsui H, et al. Survival of spleen colony-forming units (CFU-S) of irradiated bone marrow cells in mice: evidence for the existence of a radioresistant subfraction. Exp Hematol 1995; 23:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/42\">",
"      Dainiak N, Ricks RC. The evolving role of haematopoietic cell transplantation in radiation injury: potentials and limitations. BJR Suppl 2005; 27:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/43\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     MacVittie TJ, Farese AM. Cytokine-based treatment for acute radiation-induced myelosuppression: preclinical and clinical perspective. In: The Medical Basis for Radiation Accident Preparedness, Ricks RC, Berger MD, O'Hara FM Jr (Eds), Parthenon, London 2002. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/45\">",
"      H&eacute;rodin F, Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp Hematol 2005; 33:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/46\">",
"      Tanikawa S, Nose M, Aoki Y, et al. Effects of recombinant human granulocyte colony-stimulating factor on the hematologic recovery and survival of irradiated mice. Blood 1990; 76:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/47\">",
"      Nothdurft W, Kreja L, Selig C. Acceleration of hemopoietic recovery in dogs after extended-field partial-body irradiation by treatment with colony-stimulating factors: rhG-CSF and rhGM-CSF. Int J Radiat Oncol Biol Phys 1997; 37:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/48\">",
"      Dainiak N, Gent RN, Carr Z, et al. First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. Disaster Med Public Health Prep 2011; 5:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/49\">",
"      Gorin NC, Fliedner TM, Gourmelon P, et al. Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol 2006; 85:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/50\">",
"      Brook I, Ledney GD. Effect of antimicrobial therapy on the gastrointestinal bacterial flora, infection and mortality in mice exposed to different doses of irradiation. J Antimicrob Chemother 1994; 33:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/51\">",
"      Brook I, Elliott TB, Ledney GD. Quinolone therapy of Klebsiella pneumoniae sepsis following irradiation: comparison of pefloxacin, ciprofloxacin, and ofloxacin. Radiat Res 1990; 122:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/52\">",
"      Brook I, Ledney GD. Quinolone therapy in the prevention of endogenous and exogenous infection after irradiation. J Antimicrob Chemother 1994; 33:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/53\">",
"      Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/54\">",
"      Engels EA, Ellis CA, Supran SE, et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 1999; 28:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/55\">",
"      Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/56\">",
"      Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified? Clin Infect Dis 1997; 25:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/57\">",
"      Bow EJ, Mandell LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 1996; 125:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/58\">",
"      Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/59\">",
"      Wingard JR, Elmongy M. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 2009; 72:144.",
"     </a>",
"    </li>",
"    <li>",
"     www.nccn.org (Accessed on October 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/61\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on February 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/63\">",
"      Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/64\">",
"      Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/65\">",
"      Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/66\">",
"      Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/67\">",
"      Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/68\">",
"      Redding SW. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 1990; :103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/69\">",
"      LORENZ E, UPHOFF D, REID TR, SHELTON E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951; 12:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/70\">",
"      Densow D, Kindler H, Baranov AE, et al. Criteria for the selection of radiation accident victims for stem cell transplantation. Stem Cells 1997; 15 Suppl 2:287.",
"     </a>",
"    </li>",
"    <li>",
"     Maekawa K. Overview of medical care for highly exposed victims in the Tokaimura accident. In: The medical basis for radiation accident preparedness. The clinical care of victims, Ricks RC, Berger ME, O'Hara FM (Eds), Parthenon, New York 2002. p.313.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/72\">",
"      Nagayama H, Misawa K, Tanaka H, et al. Transient hematopoietic stem cell rescue using umbilical cord blood for a lethally irradiated nuclear accident victim. Bone Marrow Transplant 2002; 29:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/73\">",
"      Ende N, Lu S, Ende M, et al. Potential effectiveness of stored cord blood (non-frozen) for emergency use. J Emerg Med 1996; 14:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/74\">",
"      Singhal S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant 1999; 23:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/75\">",
"      Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/76\">",
"      Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89:3700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/77\">",
"      Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 2000; 96:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/78\">",
"      Borge OJ, Adolfsson J, M&aring;rtensson A, et al. Lymphoid-restricted development from multipotent candidate murine stem cells: distinct and complimentary functions of the c-kit and flt3-ligands. Blood 1999; 94:3781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/79\">",
"      Hirayama F, Aiba Y, Ikebuchi K, et al. Differentiation in culture of murine primitive lymphohematopoietic progenitors toward T-cell lineage. Blood 1999; 93:4187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/80\">",
"      Sims JE, Williams DE, Morrissey PJ, et al. Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J Exp Med 2000; 192:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/81\">",
"      Andrew D, Aspinall R. Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol 2001; 166:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/82\">",
"      Friend SL, Hosier S, Nelson A, et al. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol 1994; 22:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/83\">",
"      Tan JT, Dudl E, LeRoy E, et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 2001; 98:8732.",
"     </a>",
"    </li>",
"    <li>",
"     Medical Management of Radiation Accidents, 2nd ed, Gusev I, Guskova AK, Mettler Fa Jr (Eds), CRC Press, Boca Raton, FL 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/85\">",
"      Weinstock DM, Case C Jr, Bader JL, et al. Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood 2008; 111:5440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/17/38170/abstract/86\">",
"      Fliedner TM, Powles R, Sirohi B, et al. Radiologic and nuclear events: the METREPOL severity of effect grading system. Blood 2008; 111:5757.",
"     </a>",
"    </li>",
"    <li>",
"     www.ritn.net (Accessed on October 12, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8366 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0322F712F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38170=[""].join("\n");
var outline_f37_17_38170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13328959\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCENARIOS FOR RADIATION ACCIDENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Accidental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Deliberate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Radiologic dispersion devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Improvised nuclear devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Generation of radionuclides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL TRIAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prehospital triage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Removal of radioactive fragments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      In hospital triage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Safety of health care providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History taking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Initial laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      High risk populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      INITIAL MANAGEMENT DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Assessing prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Minimally exposed patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fatal outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Psychosocial impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      INITIAL MEDICAL AND SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      General supportive measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Thyroid protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      MANAGEMENT OF THE HEMATOPOIETIC RADIATION INJURY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      BLOOD PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Irradiation of blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Leukoreduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Transfusion guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Neutrophil recovery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Stimulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      ANTIBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Fungal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Other pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Historical perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H881196\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Case selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      OTHER MEDICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Immune reconstitution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Internal contamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      DISASTER PLANNING AND ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13328959\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13335265\">",
"      Initial response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13333138\">",
"      Treatment measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8366|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/0/19470\" title=\"algorithm 1\">",
"      Triage radiation injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8366|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/2/16431\" title=\"figure 1\">",
"      Serial WBC after radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/12/38091\" title=\"table 1\">",
"      Radionuclide yields fission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/49/16156\" title=\"table 2\">",
"      Military triage radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/34/7725\" title=\"table 3\">",
"      Radiation biodosimetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/28/5580\" title=\"table 4\">",
"      Radiation tox cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/14/29931\" title=\"table 5\">",
"      Radiation toxicity gastrointest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/44/33484\" title=\"table 6\">",
"      Radiation toxicity cerebrovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/21/16732\" title=\"table 7\">",
"      Radiation toxicity hematopoietic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/5/28764\" title=\"table 8\">",
"      Phases radiation injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/18/9516\" title=\"table 9\">",
"      Rx guide radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/13/36059\" title=\"table 10\">",
"      Potass iodide radiation expos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/29/11741\" title=\"table 11\">",
"      Platelet transfusion guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/23/44411\" title=\"table 12\">",
"      Treatment internal radioactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/46/28395\" title=\"table 13\">",
"      Cytokines radiation exposure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17689?source=related_link\">",
"      Clinical features of radiation exposure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=related_link\">",
"      Ethics in the intensive care unit: Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4393?source=related_link\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44598?source=related_link\">",
"      Intensive care for oncology patients: Short-term prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25193?source=related_link\">",
"      Management of radiation exposure in children following a nuclear disaster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=related_link\">",
"      Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_17_38171="NSAIDs desmoid Rx";
var content_f37_17_38171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of desmoid tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Agents used",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       No of patients",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration of therapy (in months)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Response",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration of response",
"      </td>",
"      <td class=\"subtitle1\">",
"       Author, year",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulindac",
"      </td>",
"      <td>",
"       300 mg/day (median)",
"      </td>",
"      <td>",
"       14",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       <p>",
"        1 CR",
"       </p>",
"       <p>",
"        7 PR",
"       </p>",
"       <p>",
"        4 SD",
"       </p>",
"       <p>",
"        2 PD",
"       </p>",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       Tsukada, K; 1992",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Indomethacin or sulindac or sulindac with warfarin",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       2-91 (median 20.5)",
"      </td>",
"      <td>",
"       <p>",
"        3 PR",
"       </p>",
"       <p>",
"        3 SD",
"       </p>",
"       <p>",
"        2 PD",
"       </p>",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       Waddell, W; 1991",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Indomethacin",
"      </td>",
"      <td>",
"       100 mg/day",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       4-10 (median 8)",
"      </td>",
"      <td>",
"       <p>",
"        1 CR",
"       </p>",
"       <p>",
"        2 PD",
"       </p>",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       Klein, W; 1987",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OR: overall response; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NR: not reported.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38171=[""].join("\n");
var outline_f37_17_38171=null;
var title_f37_17_38172="Common solutions for rehydration";
var content_f37_17_38172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition (mEq/L) of common solutions used for rehydration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Solution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Na+",
"       </td>",
"       <td class=\"subtitle1\">",
"        K+",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cl-",
"       </td>",
"       <td class=\"subtitle1\">",
"        HCO3-",
"       </td>",
"       <td class=\"subtitle1\">",
"        Citrate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ca++",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glucose/carbohydrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Intravenous",
"       </td>",
"       <td>",
"        Normal saline",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ringer's Lactate",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ringer's Lactate + 5 percent dextrose",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        278",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholera saline (\"Dhaka solution\")",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        140",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Oral",
"       </td>",
"       <td>",
"        Standard ORS",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        111",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypo-osmolar ORS",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ReSoMal* (Reduced Osmolarity ORS for Malnourished Children)",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        125",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ORS is reviewed in detail separately. (See \"Oral rehydration therapy\").",
"    <div class=\"footnotes\">",
"     ORS: oral rehydration solution(s).",
"     <br>",
"      * Also contains Mg 6 mmol/L, Zn 300 umol/L, Cu 45 umol/L.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: World Health Organization. The treatment of diarrhea: A manual for physicians and other senior health workers - 4th revision. World Health Organization, Geneva 2005. Available at:",
"     <a href=\"file://whqlibdoc.who.int/publications/2005/9241593180.pdf\" target=\"_blank\">",
"      file://whqlibdoc.who.int/publications/2005/9241593180.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38172=[""].join("\n");
var outline_f37_17_38172=null;
var title_f37_17_38173="Methimazole dose response";
var content_f37_17_38173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Methimazole dose in hyperthyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The proportion of patients with hyperthyroidism who became euthyroid at two different doses of methimazole (MMI). The euthyroid state was defined as normalization of the serum T4 and T3 concentrations. Both doses were equally effective; similar results (not shown) were achieved with 10 mg given three times daily.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole.&nbsp;J Clin Endocrinol Metab 1986; 63:125.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38173=[""].join("\n");
var outline_f37_17_38173=null;
var title_f37_17_38174="Mechanisms hereditary hypophosphatemic rickets";
var content_f37_17_38174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Pathways of renal phosphate wasting in hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 200px; background-image: url(data:image/gif;base64,R0lGODlhGwLIAPcAAP///9m/nZnM///9qAAAAP8AAL+/v/Xv5z8/P2xfTjYvJ39/f8q4nczk0yYzP0xmf39+VOby/4CAgHKZv///6r+9fkBAQMxmf8DAwLKZv/9+VKKPdv/v7+/v7/8PDw8PD19fX3BwcG9vb/8/Kv+9fi8vL4+/71BQUP8PCp+fn8/Pz9/f3x8fH//tneUzP+KPdtDQ0AkMD6+vrzAwMHylzxAQEP/NiId3YrCbgE9PT4+Pj2BgYP9PT/+/v/Dw8P+vr+xfTp+/7/8fH5CQkP8vL/UvJ19/nzlMX/8/P7CwsP/dk//PzxMZH/8vHykkHQ4MCiAgIP+PjxsYFPgMD6Wy32mMr8uzkxwmL/9vb/+eaaCgoP9/f//f3/8fFT8/Kv+OXr9/n15TRIWy3w8PClFHO+smL/9uSaylz/9PNHpsWb2niZ+eaZWEbODg4Nuzk9hMX/IZHx8fFelsWf+tc+/tnf9fX9/dk8/NiEJZb/+fn1Zyj98/Ty8vHy8/T+8AAN2niU9PNN+bgF9eP0M8MW9uSf9eP8Vyj6+tc/wMCtJZb/ckHc8AAG8AALiMrx8AAPoYFOd3Yo+OXg8AAK8AAPBHO48AAP9gYE8AAL8AAL9/f8+vr//w8L+Pj29fX/9QUC8AAL9vb//Q0P+goP+wsG8/P3t4c7zUyf8gILgkHf/g4N+vr/8QEO5TRGVcTj8PD9/Pz88PD58vH+8vL68vL/37+f+QkM+/v7+fn59vb58PD18PD58vL08vL5gkHW8PD/L49P+AgJ+umd8PCs8PCu+vr98AAN+fnzgkHd8fH18fH38vL99PT/Lt5+8fH38PD28fH99PNH8/P7jLs6gkHZ9/f8+9fo9+VM9eP59fX+8PDz8vLy8fH98/P08PD/M8Me9uSY8/P+9/f18AAL8PD+8/PwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAbAsgAAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcvW5oC3cOPKnUu3rt27ePPq3Yu3gYC/gAMLHky4sOHDiBMrXswYMIMAkCNLnky5suXLmDNr3sy5s+fPmQ+0xci3tOnTqFP3bcy6tevXsBM/Bk27tu3buHN7Fj3aourfwIMLH+A3tvHjyJP/na27ufPn0J3z7k1xuPXr2OcWV869u3fCzKOL/x9PvnyA6dQlZl/PHvj27/DjHw9vvr79+5zRp4fYvr//ve/JJ+CAi9GH34EI4qfffg795+CDcgVI4IQUBmZgghhmCN2CDDIE4YcOSljhiANeqOGJKNLGYYcKgehieyKSKON3JqZo442XrcgiQi/2iF2MMwaZXI04Flmkjjsa5OOSwgEp5JOwEWnklCgimSRBTGapmpNQdtmYlFSGmaCVVwqk5ZmmcenlmoiBKeab9pFZJpp06qUmm3gO5iacfI4n55V1BmrXnXkWKsCefSYqXZkeCupoXIQaiieiilZ6259J+mhHBZze8eigQlbxwANVSPqlolZsgANkG2xgRRgKTP92gwKrWvoZpjv6CAEBvBIAyKd0RdqdCVcQ4ECxD5haoKIbEBBrAgSQEcANCUwG7Qa23sroQroSAAEdvL5FByFeCOKpHRAcQi4E4kLgBSCH9Cgsdw8QgMdfNJRqwgMO9FHqBA/QYMQEAIshQMFikHqEA/k6cK+MlKLYrALNOmHFtNUGgMMgCihAwAZqJMAGrBmrQYYCZKyaRsYJpKEorix26wUh3r7FxxgQ3Lwpr16MQcAaA9ycMwGeujivckbw6kDAf10RwwPF0lBvDASMSsAEAtRLsNIExMAEEwQYATGzBDjxxBO1ehyAGmcn4HGrvCrwBAE3sO1EAmcHQAYBOOD/EO3L27bY465xeEFAHHbcQQAhAxxCQCQV1Ow4BIp7AYEgNRsd5ANU82oEDcY+cETV9Zaa9dWnb52sAwQcXPXYiTbLqxQXB6B2GnQHcG2z1bJBQMvRuv1xs2GEwTfggfM4eM27QhA5u88/P0D0BFgOgfMvHp2cCfjiYewEoY8KMOqppw7+6q2fD3ufzUrhxN+2E6D7x/PDXS3v0JKRwP5qBCDFE+6rFMw61C1BVIAPPxvAGOJQAUAQTXrSG8MY1lCBSABNczLi18BGl6wYxGBgejCC1v6iBwJc4QFgU50AWOe6ZJEoYieaGNtyp7ZmDWIDb+NdAHjnNyewYQNhWBW0/wjgMuQlT0nL4xXO3nIHBMYBaBCs2R0ceLh4YZBEE2AdAZjgQhr0gVdMEBX5TMC6K3xRhSxU3wvJFivfoU1tATDeE95nvx3+LgBseF/Z+qcGXtUuUQNkELAepT1lBQmG2cqM76QlwCMeZJCOKqQh15dI3QyCfo10ZEEgKShJTnJEiKykKCkTyP1wMlCe/CSFQjnKVp5Hk5s8JZ1SqUoCsdKVoixlemQ5y1oq65a4TKQuqcNLNNHSl/IBZjBtNczeFPNMx0QmfJS5zEzC0kzPzFI0pekdalYTkNccSDa1yc1CefObfGrmaMbJpG2WUznnROeb1NkWdi7Jne9ETjzlGf8merLFnj7CZz6Ns09+TsmfawGovAa6poIa9EjhxKZCQSRQhr7GoQ+9EULVMtErWlRIGM1oijaalo5S9KNQCqlIT0RStJj0QxVF6alWWs2WnuWlEIqpTJdF02Xa1Cw4fZBOdyqbnvo0ogB4lA2us9TrDJWoh1GpURH007I4ygYoUMJwvtCFH0GVklPNJVIfZYYRCAerTbXOU78KnrC6sqpk+VQTNBCcuWZnrWwVDHM2sL8E3OBife1rqxKALd1lzK0sHatSC5BW1GigCevBa14dExloua9sAehVr/Z3x8zKD7GJjSiwHtuC1JAABY1V62RXWdk70hEyb4MMtDLGK9D/hjacgxyBGVDTgi58gT2SXS1zZhuA96UNk5btWG1tmyG4jmWQSkABCU5TVhitdkLDJcBlYwVb5GpXuZ9l7pgU+yDNmve852VEMSSB3vYS4BJ+YK9758uu1Vy3RK1VgF8lE9v50Ta84j2Qc8XyIQJUhAc8eAgHPPADiiygvncJ7mSze9jI9Je4ng3weEULIQNTZMENbgiCK/LgvEg4r8yZ1Q0oA6taqRi23NWwgsjrIA9T5Ace4ABD8iAEHTsYwqC6r4CkKuMN0fg/NqYIFpCwEC54oAcWKbF9hRwfIhd5URwu70U4IIQoKAQJWLiIlCNM5WReGZxZrjFGeuCBJSBk/wtE8DGJgVyXE7PVymfOzYDDUuCMwPkgSyiAm8VM52CVucqbwUH/8tzcI/snyRYhwhYMIumMjDnIh+7mZijG6EanGckaCfSgBYIFImjk0nXONI02XdhOU9XRdClrFt4i6yyMYNZwGYFZB2BrXMMF0gwBAQKGvYAOAEAHCEhBFITQCQSooAd+4MWwEbACYctAICJwtkNQbWhVd8dNnHb1qz9dl+hmNQsFgKwGCkBXuBSgAG9Zd7t/DZEO8GoBJSAACACQbwMAAAmVIACXGfGBaQMgBQRgAQBAQIAUPITb2vH2t1kt7nHjVi9zSDcKsjoAecfl3fFmt1yArRAZEAABAP8wwMnt7WFN+CEadZgEARZQEBacvOEQgXiEJM4dNw2iiJVZ2R8hw4YE1KrioNkzWPhihnfPIeTzHsC7py7yuJA8ISLQtwzyvQCTa/YSHvDANjTr8IPzquwPr14FyMzzIW1mf5bxHdAjYwUnOAHpKoJ1XUbw7nZ73N3s1gDfoz6AqyMEAZoVAQAWcPIFLIAFkigAD+7t+BUAoAP5JoC/c04ICIzBC2vvdtvns5k0MJIyUojxZJq1YrzvRu9zWXchmlCA6f79LSDveNXp/RBeGWDzAED85gkwiTp44BIoHwjmP5D15D+cXXSIRBz4cEFIjV6fm9nA3SnTLDZcxgmqt4//G+TwHDm4gUpK/4peSFCALrTABgVAQQvWPXW65v72bzG8QVRegoLwytgGwAg9lgl+4Ai8wgLLpwId8AGal3NAtgZx8ETWd30EtRlWAGCtVTuw0jGRYTwJoghA0Bxy8Ajnd1CwFxdfoAFNNQcaMAckoAEwqAG2124vOF1W9xAG0HUEsQILoAMCcQt+YAwHtwyw4HgpIAMLoAICgYTX9nxzsQZeEAffQhwUWIGb4UOUAS2RQS1wJ1sYaB+BUACBkBt/gAgv0E8nmB36FxFEEGYCwWVeZmmF9hYV0DMQYApVGBt7UjyUgTuLVhlk8AQYMoIlaBuKwApikn5e0Wd+ZmoE/yFqcngXDRQDeGAwykEDDpCJmriJnNiJnviJoBiKnkgDE5doUkAZftN6lSEFg2AZs9IxsBiLsjiLtEiLmIAKtZiLsjgNi6CLvviLHaOKeUdu/bGGDgGJBfFnGKFzcSENo3MElngcE1ACv1eN1niN2JiN2riN3IiNJYA1PdcZUtBqFkY7lXEDmJSFINCN7NiNmuABmdCO2cgJBaAK8niP1wgCFZZ0aYgdxsgQHEAEcUhpk0ZoJiYAYnAEMXAE4BgbE+B8OYEADel2nJEApxcZfnORkIEDT9CKlpEANCcSeZBjEhGQAwkSC7CP2kKM7fGPC7FkCbEET2aQU7YvMeAAE//ZGg/JExJZihZIAH+Ika4yGTgwlB8ZkhZRAAsxYhEBkyORkpeCEkq5FYxYEWzGBQqxbHI2EcwIFwFikw5gOjoJkQIRBVsJEz0Zjp0RBhppGyCJEVOZECAGEVdJElBpG4oYl1lRlRPBZXnAEGAWZXO4c4RhBF8jNqyxkwWBBCEmE2kJT55hBU9Ajm6JlBWhlwhRlw3hlyVxl7WRl1zBlxLBlAsxlz92kIZhmExgBNwDGNFIGIpJEAXgho6Zk6TnGWlgjrjxlheBmQjhlAxBmk+pkq93Er5pFaIJETh2lgmxnKc5ZYaRRU/TmkxwBK05GLEpED1QAEJAE49JkZ6hAGH/kBu8mZSb2WUM4ZydSZydAZpU2WGOF5/yOZ/0SQ0eAA70mZ/xOQ7koJ/+GZ8IMJgTmBjS+QAlZELXGRjZCQBY8G5YWZs+2RlsI4y0UZ6XeYxtphBO1ph2yZ75IZWhCSHXM6IkWqImCgHDAA0nuqLXYw1dEAssGqPYA52JQQOj0ysxQIqCsaBE8G5/CaFq+Rl+c3QVapkUcZxv5ogIEZgn4ZnDaBJIShWDxFWlZRqnpVWRlZjmFQNi+RfZyQFTl2BACpm0cQNoU5lwCRGVdhBaiRJOyo/GGaJKJV2pUV1Z2hhaZF56oKAQ+QNT5wEz8Z3YVxtmSqGdYaEREQVUVwAF/wkAPFhsKbcAlgcAMgllBGFyk9ADj9qDlqdyRnpqHroZe1YLiwoMAtEGEpCqQ9AGAIABBCABGOGqsKoQPoABrDoSwGJXqdECuupVjQEwR1AsmnUEgJGddUB1o/YSgnqbtcEGTzB3h/qpDxFoyDoQKkcAisd4wNemA5EDjjBpKldwBPABK9ABBjCpHfGmKzkSobCooSAQrloDFkAANdAGshqrr7oQ94qrj/JYwAF/qdUksSEw/HKT3JOdQkB1J4kQK/B7EPF76JpyBmBsh2ebVmgbOJB6Q/d20voQHvCnBHGtBKAC2spvvOIIuDAQK0AAyiAQKodyWZeEyfYR6lqcJP+xClO3CgPhqhYAACHwqq56AjNAABbgAwAAA0MLBVoAAD4QAjVAAEoLAxYQAkMbAq1KAEJLtEY7tFC7tEnbs1JLr1bLEXMasKfhr76KHCZwsM7HBYvKZC5rXpeHeL3icIzXK2QJAAx4dgCgAprVhAaxrBdrG6/yrJ6BqBHBA2Easvr2ASVQsusoA5AXYoz3CnELswSgA55Ks6GqGUrnCVPnCTtLtD5LAEPgqlAgAUM7BABQA1CAASdAADAwBEA7BFrAs7BLAEmAuqprugCwAxiQBFBQA79LtLBaAzOAATugu2QrKL31W8KhW2krGFLTpQKwL3t6GAv6b5ZqrQkXn8H/p28d0AE64IOMhwBGaBDrqAPj2rcLYADNV7ERehsb4D6F5SxpQKSSgbgQkQdT96Nx63gJ14D41is5xgEskAPeK64fYK4zx7lReREYUAMnsKoJIQpTJwqjK6/0Wqv5Kqv3KqtJwCsWsAMeDKsg/MH52ru8crUoDLUWMLSzqhGOogSFYB1KgAbTGxhXwAQJ+hdJY707mrdI0L1xS40GoAIrq3AFwXjreK4IYW8fMBAk+8AHIbh6+Bw3kHro2CsdWTf727EO4bYOyrg0Z3Oax77FhngIBgo4F7cs0IMAaMXp2rmhga+9AgU7oAVGSxCpMHWpMLqpOwRGG8KvCgMEYLUj/0zIGNC7J3Cvi2zIEkC7EuAD8+rCR4u1GLDJt0rDQfUfIpI0FrtCTKC9RGzEKadZCPCyAJBtM3u395YC06aEAsF4SIl4LEDLgXsEo9LLvvzLwBzMo9IKgVXMxnzMyCwF7iUFYeB9/AsRCdudZgwAXmcA7JsDIsCAXCYOU+y9ELm5HrEA+oXM5BxYpZCq6JzO6rzO6by86DUDIYABA3EKBXAKBMGz96zCsDoDNaC69aq6EvCz8Wy8NVCvkky7J+C0BobI8AwAQ7sDEnACM5wRnwzKhHEshlEF5AObp1wQ/Pd7SpxwB4d4NOfEEJuDlVfL+lYQUnx4vCzMMB3TD0DM5f9c0+XcXvolRGLsEMdaBwWhAjO7cNqWbSAgbByQDdhKEECteFQc1Ok6zjaNzOfMzlRN1e5sXhQ8BDAwEJZQAJZAEFI7tgIhtUtL1kwbAiW81TCwAxZgAazLsxZwAmptAWVN1z5bwmwtEBIQ10w7BG29A1u9ERXtHyJiL/iiiYhpAq9TGNtbxB59cgSBeCLQAba8eHTM0gy3yhObAprLvt0cuKMcJeOhWU7QzNay0w3hpxz6EDwQcNzQEjXbnnhMwhIgzwYxCgUwCh+xrzcx2P1R2C6UMOIDGIvN0Qbh2IwLkR1At3xb2Qchsr7HvrzyAWhXEFgs2uIhBWTwV0e5ZQX/wJw75gG2YABrqhKx/aESDAUhkAR9jBCbUACb8BFmjRO+bV2DsZCGIQYEkL3GvZiobK66rLIOKxANG7EEYa7WaGwNO7EJcd0XlSHPDBE+HRFOZqnImBLnLaoo8dXvWd93RRh9UMqFkTQ62t8EgdxjCp4IEuEKJhFMKhDKiOF2jBmKGN8d7uFOBZv7XRhM4ACmzJOh/eAYwuIMoQLA9xBREGcF0YYS0bAUy5UzniM6IQEEYNsbYa+FnK/8iuM5DuI5OhijU+ImHpFB7hp4loWovRCIFxEXPhAVHhEl62BRbhmKKBFUbuUacedMa6skweU7DBgmMAFifr2CjhjbaxMO/27mEC7GHQACDFgC5ZoD46p4KcCAySbLKQACKaACaFwCSpht2UzdKZd5KEcKrsB4uXx5ks582IYAMpADKWBzJaB4kptwDpdtrx7gBJHhnosSaJ0Ech22NTC2XKu0AEDlO1DQS9sGsUsAMwADPhC7wy4Qvy7XaE3lUAADMAAFzh4CZh3tYisQJRy72e4bfq5a3XHoNZHorXHmp50QDKe5OWAAko6EmWsANve+qJ5sJGsACKfAiKcLz9C+H8ACBiAD+4Z4u2By/VfvjOeDiFcCro54mu6365hvy00AEq/rA8Hrd3wS8zoDFgADyKu8zAu8wku8VB7P3A7uu+vtsZsEVP/OuiE/8vOqBSM8A20wr3t8rzE/8wAgtrF7AuZ+7gKb7nmL6GXe7oueEBpPEJAd9Ci35pa9eY2OxlNPAB7ABWuebyzg6uHLYGse9ZBN9VVv2RJvcwZg9gjh8TSOEpd8tVAQwyvMtQam53f+s/IKq6Qb9D0b9wAQ95es5/fa96Rr+D1bEUY/HAKl7t659Kzh7mGcEI4rEONb+fYG8B4W5/Uu9eHrZWu+Ajrg6COLeDhWAlOM+QSg+R3fgGpcjRm/EG4v5SDvYYj8yJxMyZZ891VeutCuBSHA7UOAvEyLtYFvY3HPz8fe+/dK/D5g/Ihf9Iv/G42f9OsO+TOVIBGedTn/8Hjwi62dL+kiYO+bJ/6ZDQDa4GFr/gEggG/kStLdkNRZJwKdb/bXrAMr8AHMh29rDxAEAAwkWBDAggQBFC5k2NBhgAMGJU6kWNGgBYEDZxDYIeGEhCEEToSoIVACxxAEZgCw8PEEgSQpQ7xMwjKjTY8EQgAIeWIIBgISAMikCYCAhYFHLS4FMMDpU6hRpU6lWtXqVaxZtV5tIMDrV7BhxYIVYwSP1wkImK5l21Yigglj5c4Ny+DhXbx58yZYYDFFDgQgOgDQgSCHjIEqAMtIgUDFwA6AFyAQ8cOXWgAi1BYO/BgBARAInEUZWPjwQM0EO4Tuu0Iz5Q6pLSLUqzei/1vcEkMgHehjiAULO2AMDb4DqZaWwX0ASHKiZU2ezwfuJojRuFAAPq7DsKBl4O8T0C3sZEk+98Ct6dWvZ9+eK134JqocYUIgBg20mM/vPw8X/n+x7KptQAIZ4ou/tjjw4AemPhuoBw+4QJAt2gp06LYJM9SwIow2RNA9EEMUccQBugLwK/nwuIIAFu3DLz8PYzTIvxNPFNBCHPE6UEaJeOBhLdkAwIIIHiWqMEeFMCxySdyoY5ItEqOUckqpTKwxhhZbvA+stJ7ckMYa/7sRSTIV2pHJKITg4DwitvDySCSV9HJOOvmj8k48Q7TyxAeyJOAKE8KaoAQDCjX0UEQTVf90UUYbRbSEuMIUs0xKA0gABEczdVQTDzLRVFFOClDlU1IRBSGhMuWsc1VWl8rzVVi12hPAKrIEVCwaHNB1V1579fVXYIMV9tcXJaVrzEpxvEEBZpt19lloo40WE1SktfbZXhY55lpuu1XgBkpVbXVccpuK9Vx0oZqVrgkcYAIPFm81dl56660X2WTzzRcIRZItghV9A2ZI3HILpjNdhM9ddywxjojhgUAdkNdeiiu2uC6BMy4zkAICSfYPRF7QWF+CDTZ5yYRTznNhsEx4IIYjAvWKBpkv/o8Km3MOcGSeC1QECH0hecSNnsM9+eg5VbbKjBai/MIGPFn2yogYHCj/VucaEzkDa6zxLfprhdyARGA5iAY7x5KRVntCpatCAw0SSUBBiajlmoAJJiLlOswyLtg7Z6/PFnxwwhdKe23Ec2ubqhZQyELExh+vO6xcYzDib0mDKMAFzC8OvHDQQ9f48MRLX2txquSmG8S3X93TBIch7jzMRgooYPaKPxd9d97JJN104ClCnSozRgBxDhSaXtkrl2EWA/cw37C9Eejv7f167H0Pfnu3hp+qhS6+aE8JFEiAtSsjmHBA7+oBhMP2RNqfV/fs67cfIu7zZ8r7qWwoAOr1jMAMsQrGFZhQBfnViAq2K0AZEigp+t1vQEAoANACYDuFYDAAFARaERj4/4ixBcCDIntBAYogQfzpT4UT4d9UNNCE9XyhC8rDkx0AEQM9PLBGYGBgAYKgQxuhkFIczGABiqgQInpQDpAoACIUMsIAlPCEEvzdCk3Xwqk0QQPpsQEKAHgnOhCCAIQwhVz6dLmWXSEGNZvdHnoIBiACKIJCxAsFKfGCEhrxggXAIyUqKEI+uqGJTyyAHF4gBxOisIpWTBwWpUI+82lFi3mCwBgAYYcSMYwAZxGLCWBWvSn08A1xnBQdkUTBHuoxlX/0oCIeUYAQerCHU7zfIhm5NoRVQJe75GUveXmNLlTDl8P8hjCGeUxe0gEra4iDFyrwlIU5jI1g6dPzZkcFF/+4AA5wcEH8SHksU56yAHfMYxH7yEoTNtFsSjxkIql4S0YijAAIoGc97XlPeyIjF/jEZzI8QAp+BrSeH3hmVSrghTisISoLY0IfmDcBiFqTBgRAI/Qu4LdvwmeO4WwIEfd4xA2i8wXecCcUpahIeFpRnudREIMqwgEhkCY3CCioVOwgiDFAYCoLI8AD0NIin3qlp+27aEY1ylEceVSDGkxiIBFRSECS0J21TOkKV3qeH3hgTRTBAhL2Q1Op0AECBBCEMnc6lqHOJa0WxahR5bJRpCrkDy/4g0LwaFeRBWCudQ3EC4g2V5H1lWhueIHH3llV/V31PD6iSFYl1J+aOiX/EmPwAiarsrArOGAuEyAAAqtXVPg0wgVwlEsQ9rCHv8E1rqtNli0RazDF5gamMi1IS/kDVqdUIA58iCxVFlZNuUiTqG0t7RQ4B5YL4OwrZygAcQHHWuh+zbWvLVdscwOhxxKEsbd95h28MAaFZmVhntQsrtbKVvhcoADK/UoBMhCWN0zhh12Lbn1HNl3qjsu6uelqQfKgJgQhYA04hYBZxSuXKjigoszrg0PlB9q5lOG4YHFvWDJQAOrR174bJll+tycVFBQAbk4ZAQO7IDnbOUUDBdhiiW13YqncpCIraNEHBDMQEMyzTToggCP8gI0a92UgK2ABAVawlM8IwrJb/5GaWwUAYbk09yvq7eGEBSBlDXNYy6nycPCiMgcGKq/EX8hCAVDglBQPYMUtLgCZzRxjpqRgngbIAQFyMJAiE2AJBXAFATCBhRyLQAYfIMBjSsAiFjToEOxpsluhPBYsC4AKGbiwITKwtfY613Nb5nScugy8qKChAIVoM4kLQIIWvHkAtiMBCUjNZlSrGioypkiOdQCADrAIADQmtAFmsQhGEIEDRTY0AQwAAAPkGAQN6q2snDyXR4sFDqgNS4XBwlzS6ky1ne40fj99sKekGg3+g+EAStyELhQAxalkM7rVDeelEDspHwCAnHnMgg/IogCcoDEBJkOAEhAkxylgNv+jny2XaMNXvmFxAaanvF6ubZvbW/b2t70ElS8UYAQr/p+5NW5m5bHa1Sz2eImTB++K5JreAJABaDJT6EPLoBkFIEbLEX1jPBe64OtptFETDpYFenMuQZjCKCM+caTbxuKNfEoXUDCCETRh1B4ngaiNt+oCqJjkJa66xlFOkZarxQAf+MCRD11vHWAB2ELohL8lwuu14FY9Pc/oz5FbgGyLJQhlWPjRk/73Cy0dcU/xXyGcooQ3c71xpU7zmqm+ePHNeikiyJJjcD3PB/nBEQjgwSSMbZBDI3rncz/4WOzuVokDProVF3yRnqIEEqxuAK1ugQ1QPQDYm6/Vh4/9AGz/37TcR4XWElGBoY4MGQMcGabhSL6CQCGRQz0Gyc0+cOnDcnqjpl71rGV962W0X9zU4UcEyepWv0p9rND9m9jPqPa3H9fue99D4G9L+Q1SB69y1+DWR66mD+7+9+Oo+JM/DaG/tbAtg5gt/eM5/uu/BvQKAAxAUxpAAmSbdBm+tuCBOqAI7Dq//XtA9vumCJRAIaLACrSTC9yPNDE/idgCIoGsD2zAECSlESTBwzrB6krB3OACD+iBpWgTGGTAB3wy/3u2GrRB+zFBHFScC/QTJ3xCAliESoDCLPmEAvgEKsxC9HuPIZzBODpCJMweJVzC7nGkqHghrfiCJqCh8xlC/yIcQjAMw+sZQzKEEjMkvI7TCgFCF/UjJS8EojiUQ96hwzrcnzscgBaYpK2AJIVxwz/UoUAURNEhxEK0iEMcgOJZjyw4uTYcQipgL/6LREkEHUqsROG5Q9Vhj9bpRDeEw1HUslI0RYm4Q/CRnPVonDlgxVZsQFF8xcGJRVksiDtcxfZIxeXZxQfsRV88G2AMRvRwJORhQ/bIxGNExlBcRvtqRmd0JFyEnPCpRmssPWXExqLRxmB0pD0ckS76oinpw79xoyl4ONuBA4y6sONygQrDx3nMuwQaR3LkGXOURUfKAmk8noIkEXfkGs2ZHq9QrzfIADeKH3v0Cnx8L3w0BP8eikdA/EfoCkhTvESQzKQ4MoQCkB5qUy+MCqVJayBKK4N8dC/N0UhI5Ejuc8akCclDTEis4TsBCKUfQkmKdK8LSyWLbKD34Uf58UeaFBiPrESczMk4Yi56fB9DeDIsc8kzuLAyaMmXxMe+m8mlRKqmLMSnvEOdzBnpySZ8hAOr9BuS5JyJFICKlEv3ciMr68ewFEubvLiydKSztJkpYEuveJ8zoDLbcYEfisu5rEiiK4CqBMu8nMC9fJK+9EsgCoJLW64M+ERK28yvwExMy8ofEk1Jo7SNjEzJnEyUqcwW+stwxB2lRE2jUU3XY03+cc3X7JzYlE3toU0esc3bzE3/ceTNEvTN3wTO4cFNHcLMDJgv1CNOlDLOGEHO5HSroewhw6wwMAilApgCpPxC6LxB6SxA6lwc5cwZKrgo27morLSd5tTKIKACl3yv7AtPqhrPDSlP8zw426Gw2xEA6SEtHjK69rPPJMTP/NRPpTlPrOnP9vrPuRSAuCxQAxVDBCVPBU0ZBtUZB/UKBw1QrxjQ56xQ7BnLOsxQldnQnOnQK/tPrfzE+RxREu0dEyVDFNVQ/nTRHnqv7bQd73Sy3ZzRvKjRJbzRhFFRmzFNAWBOSnNOJQVSIaXRC80QI0UYJBXOTYvS3SFSHKzSdLlSLM0dLd3SKbVAL40VMA1TewnSuTFtCC49wTNtRDWtzzYlxTL9kDjVxTkFzzotnDetwDzV0z2FzD4VnD8lQApIVEVdVEZtVEd9VEiNVEmdVEqtVEn9hQjIVE3dVE7tVE/9VFANVVEdVVItVVPVVGY4AFVdVVZtVVd9VViNVVmdVVqtVVu9VVzN1VmlhTvtVV/9VWANVmEdVmItVmM9VmRNVmVdVmZtVmd9VmiNVmmdVmqtVmu9VmzNVm3dVm7tVm/9VnANV3EdV3KdzIAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Levels of FGF-23 are increased by inactivating mutations in PHEX (as in XLH) or DMP1 (as in ARHR), by activating mutations in FGF-23 (as in ADHR), or by tumor production of FGF-23 (as in TIO). Each of these disorders leads to excessive activity of FGF-23, which suppresses the Na/Pi cotransporter and causes renal phosphate wasting. In HHRH the renal phosphate wasting is caused by a mutation in the Na/Pi cotransporter itself.",
"    <div class=\"footnotes\">",
"     XLH: X-linked hypophosphatemic rickets.",
"     <br>",
"      ADHR: Autosomal dominant hypophosphatemic rickets.",
"      <br>",
"       ARHR: Autosomal recessive hypophosphatemic rickets.",
"       <br>",
"        TIO: Tumor-induced osteomalacia.",
"        <br>",
"         HHRH: Hereditary hypophosphatemic rickets with hypercalcuria.",
"         <br>",
"          PHEX: Phosphate regulating endopeptidase on the X chromosome.",
"          <br>",
"           DMP1: Dentin matrix protein 1.",
"           <br>",
"            FGF-23: fibroblast growth factor 23.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38174=[""].join("\n");
var outline_f37_17_38174=null;
var title_f37_17_38175="Postoperative splenic shift CT";
var content_f37_17_38175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postpneumonectomy shift of the spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT scan demonstrates the postoperative change in location of the spleen (arrow) and illustrates the potential risk of splenic injury with blind chest tube or needle placement into the postpneumonectomy space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_17_38175=[""].join("\n");
var outline_f37_17_38175=null;
